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Atrial Fibrillation is the most common clinical arrhythmia and affects over 30 mil-
lion people worldwide. Atrial fibrillation is a leading cause of morbidity and mor-
tality worldwide with death, stroke and heart failure being the most feared com-
plications. It is a well-known risk factor for stroke, a risk that can be reduced by 
about two-thirds in high-risk individuals with oral anticoagulant treatment. Atrial 
fibrillation patients can be asymptomatic, and many individuals-especially the elder-
ly-are unaware that they have atrial fibrillation. Because atrial fibrillation is a com-
mon, chronic and often asymptomatic disease, with increased risk of serious but to 
certain extent preventable complications, it seems to meet most of the World Health 
Organization’s criteria for population screening. Screening for atrial fibrillation and 
initiation of oral anticoagulant therapy could potentially prevent stroke from atrial 
fibrillation in high-risk individuals, but the optimal screening program and strategies 
are not yet defined. Several large-scale, randomised studies are ongoing with the aim 
to answer the question if we should screen for atrial fibrillation, the STROKESTOP 
I and STROKESTOP II studies being among them. 
AIMS
I. to study atrial fibrillation detection and predictors for new atrial fibrillation by 
using the biomarker NT-proBNP in a stepwise screening of a high-risk pop-
ulation and to study oral anticoagulant treatment uptake as well as one-year 
adherence to treatment in individuals diagnosed with new atrial fibrillation 
during screening.
II. to study atrial fibrillation detection using pulse palpation and compare it to 
single-lead ECG and to study if symptoms of palpitations are associated with 
atrial fibrillation yield in screening.
III. to analyse geographic and sociodemographic disparities in the uptake of the 
STROKESTOP II study and compare the results between STROKESTOP I 
and STROKESTOP II after the intervention of adding two screening sites in 
STROKESTOP II.
IV. to study the potential yield of detected disease in non-participants and to com-
pare characteristics of non-participants to participants.
METHODS
In study I all 75/76-year-olds in the Stockholm region (n=28,712) were randomized 
1:1 to be invited to participate in the STROKESTOP II study-an atrial fibrillation 
screening study-or to serve as control group. Participants without previous atrial 
fibrillation had NT-proBNP measured and were stratified into low-risk group with 
NT-proBNP <125 ng/L or a high-risk group with NT-proBNP ≥125 ng/L. The high-
risk group was offered 2 weeks intermittent ECG-screening whereas the low-risk 
group performed only one single-lead ECG recording at the screening visit. Partici-
pants diagnosed with atrial fibrillation were referred to a cardiologist for assessment 
and started on OAC unless contraindicated.
In study II the participants from the STROKESTOP II study that did not have prior 
atrial fibrillation diagnosis were included. Healthcare professionals at the screening 
visit palpated their radial pulse for 30 seconds and recorded it as regular or irregular. 
Thereafter a 30-second single-lead ECG was registered. Patients also answered the 
yes/no question if they had felt palpitations. 
In study III data from the intention-to-screen group in the STROKESTOP II study 
were included and the same data variables from the STROKESTOP I participants 
was available. In the STROKESTOP II study, two additional screening sites were 
used compared to in the STORKESTOP I study, closer to low-income neigbour-
hoods. Invitee’s residential parish was used for geo-mapping analysis of the geo-
graphical disparities in participation, using hierarchical Bayes methods. Individual 
data for participants and non-participants were obtained from Statistics Sweden with 
respect to following socioeconomic variables: educational level, disposable income, 
immigrant and marital status. 
In study IV anonymised individual data for non-participants and participants were 
obtained from Swedish registries regarding socioeconomic factors, medical history 
and dispensed medicines. A random forest was trained to predict propensity scores 
for participation. The propensity scores were used to infer on potential screening 
yield of disease among non-participants. 
RESULTS
In total, 6,868 individuals accepted the screening invitation to participate in the 
STROKESTOP II study. Participants without prior atrial fibrillation diagnosis were 
6,315 (91.9%). New atrial fibrillation was diagnosed in 4.4% (95% CI 3.7-5.1) of 
the participants in the high-risk group. In all participants without prior atrial fibril-
lation new atrial fibrillation was detected in 2.6% (95% CI 2.2-3.0). The screening 
procedure resulted in an increase in known prevalence from 8.1% to 10.5% among 
all participants. Oral anticoagulant treatment was initiated in 94.5% of the partici-
pants with new atrial fibrillation diagnosis and at one-year follow-up 96% were still 
adherent to the treatment.
Of the 6,159 participants included in the study II, 461 (7.5%) had irregular pulse. 
Twenty-two (4.8%) of those with irregular pulse were diagnosed with atrial fibril-
lation on single-lead ECG rhythm strip. Among those with regular pulse, 6 (0.1%) 
cases of new atrial fibrillation were found. The sensitivity of the pulse palpation 
test was 78.6% and positive predictive value 4.8%. The proportion of newly diag-
nosed atrial fibrillation was not different between those with and without history of 
palpitations.
Higher participation was observed in those with higher education, high income, 
among non-immigrants and married individuals in study III. Participation between 
STROKESTOP I and STROKESTOP II improved significantly where additional 
screening sites were introduced. These improvements were generally significant, in 
each population group according to socio-demographic characteristics.
In study IV the atrial fibrillation prevalence was 17.9% among non-participants 
compared to 8.9% in non-participants. Non-participants were in poorer health, had 
lower socioeconomic status and were less mobile than participants. The most import-
ant factors to predict non-attendance were low income, hospitalisations and higher 
CHA2DS2-VASc scores. The weighted estimates suggested that the estimated yield 
of untreated AF was 3.6% in non-participants compared to 3.3% in the participants.
CONCLUSIONS
In an NT-proBNP-stratified systematic screening for atrial fibrillation, 4.4% of the 
high-risk participants were diagnosed with new atrial fibrillation. Oral anticoagu-
lant treatment initiation was well accepted in the group diagnosed with new atrial 
fibrillation. 
Pulse palpation was inferior to single-lead ECG when screening for atrial fibrilla-
tion and we would advocate the use of single-lead ECG rather than pulse palpation 
when screening for atrial fibrillation. Palpitations did not predict new diagnosis of 
atrial fibrillation.
Decentralisation of screening sites in an atrial fibrillation-screening-program 
yielded a significantly positive impact on screening uptake. Addition of local screen-
ing sites in areas with low uptake had beneficial impact on participation across a 
wide spectrum of socio-demographic groups. Importantly, decentralised screening 
increased substantially the screening uptake in deprived areas.
The potential yield of untreated atrial fibrillation detected by screening was esti-
mated higher among non-participants than among participants. The non-participants had higher 
CHA2DS2-VASc scores, underlining their high stroke-risk and probable benefit from attending 
screening.
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1 INTRODUCTION
Atrial Fibrillation (AF) is the most common clinical arrhythmia and affects over 30 
million people worldwide with a global prevalence that is increasing (1-3). AF is a 
well-known risk factor for stroke and a major cause of cardiovascular morbidity and 
mortality (4-6). The combination of increasing prevalence and serious complications 
of the disease make AF a global health problem and a burden on health care systems 
around the world, see Figure 1 (7). A non-infectious pandemic, of sorts.
The 2020 European Society of Cardiology (ESC) AF Guidelines highlight early 
diagnosis, integrated patient management as well as prevention as key messages in 
AF management with the goal to reduce the global disease burden (8).
Figure 1. Global prevalence of AF. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atri-
al fibrillation. Nature reviews Cardiology. 2014;11(11):639-54 Reprinted by permission of Springer 
Nature
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AF patients can be asymptomatic, and many individuals-especially the elderly-are 
unaware that they have AF (9, 10). Unfortunately, AF increases stroke risk regard-
less of symptoms (11, 12). In about 10% of all ischaemic strokes, new AF is only 
detected at admission (13). Oral anticoagulant (OAC) treatment has been shown to 
reduce stroke risk by 60-70% in individuals at increased risk (14), and calculating 
stroke risk and initiation of OAC treatment when indicated is considered one of the 
most important factors to address when new AF is discovered. 
Because AF is a common, chronic and often asymptomatic disease, with increased 
risk of serious but to a large extent preventable complications, it seems to meet 
most of the World Health Organization’s (WHO) criteria for population screening as 
defined by the Wilson and Jungner in 1968 (15).
A study screening for AF in elderly subject through pharmacy-based single-lead 
ECG found that in individuals diagnosed with AF through screening had a signifi-
cantly higher mortality risk during 1-year follow-up than individuals without new 
AF (16). In a Swedish AF screening study with 848 participants the stroke incidence 
in the intervention municipality declined significantly compared to the surrounding 
control area after five years of follow up (17). This study, however, was non-ran-
domised, making causal inference difficult. An observational study on incidentally 
detected AF found that OAC treatment reduced both stroke and death, suggesting 
that AF found by screening would have similar results (11). 
Systematic screening for AF is large scale and expensive, making it necessary 
to study if it reduces stroke and death and if it does, how it can be done cost-effec-
tively for the society. N-terminal B-type natriuretic peptide (NT-proBNP) has been 
shown to be one of the strongest biomarkers predicting AF development (18) and is 
associated with increased risk of stroke and mortality in AF patients (19). This com-
bination makes it attractive as a possible aid in identifying those at highest risk for 
new AF and stroke and possibly at the same time for reducing the cost of systematic 
screening. 
Technologies for detecting irregular pulse and for recording electrocardiogram 
(ECG) rhythm strips are rapidly developing and could potentially be of practical 
use when screening for AF. The 2020 ESC AF Guidelines recommend opportunistic 
screening by pulse palpation or rhythm strip in patients >65 years of age (8). A study 
showing only 25% sensitivity per measurement compared to single-lead ECG when 
performed by laymen indicates that pulse palpation is inexpensive but more difficult 
and less effective than one would think (20). In comparison to several studied tools, 
such as automated blood pressure (BP) monitors, single-lead ECG, smartphone apps 
and smart watches pulse palpation has the lowest sensitivity and specificity (21). In 
3
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an era with abundance of detection devices using rhythm algorithms, pulse palpation 
seems like a less suitable option with its low diagnostic performance.
The success of any screening program is dependent on participation. Socio-de-
mographic factors influence participation, with lower income, educational level as 
well as immigrant status being associated with lower participation rates (22). Lower 
socioeconomic status is also associated with worse outcome in several cardiovas-
cular diseases, including AF and heart failure (23, 24). It is, therefore, important to 
study which factors influence screening participation to try to infer on what can be 
done to reduce this socioeconomic gradient on screening participation and disease 
outcome.
This thesis focuses on population screening for AF. We studied the yield of step-
wise AF screening with the addition of a biomarker and studied the initiation and 
adherence of OAC treatment in participants with new AF. We compared pulse palpa-
tion and single-lead ECG as diagnostic modalities in AF screening. Lastly, we exam-
ined what influenced screening participation and aspired to infer ways to increase 
participation among individuals at the highest risk for AF and stroke in possible 
future AF-screening scenarios. 
4
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2 BACKGROUND
2.1 PRESENT AND PREDICTED EPIDEMIOLOGY OF ATRI-
AL FIBRILLATION
AF is already the most common sustained cardiac arrhythmia and is expected to 
reach even higher levels as both prevalence and incidence is on the increase (2). 
Chugh et al. reviewed population studies from 1980 to 2010 and the estimated num-
ber of individuals living with AF in 2010 was 33.5 million; men showed higher 
prevalence than women, developed countries more than developing countries and 
older age groups more than younger individuals (2). In Sweden the prevalence in 
2010 was 2.9% in the total adult population (>20 years) based on the in-patient 
covering registries, increasing with age to up to 14.3% at 84 years (25). The range 
in prevalence is quite large, from 0.2% in adult men <35 years to as high as 15% in 
men >85 years. A similar trend, albeit less common, was found in women in a 2015 
study of on over two million citizens in Israel (26). AF prevalence, however, might 
be underestimated, as the disease is commonly asymptomatic and often remains 
undiagnosed (27). 
Risk factors such as hypertension and obesity are growing problems worldwide 
that promote AF and can also influence the incidence (28, 29). As the global pop-
ulation ages, the number of adults living with AF is expected to double in the next 
30-40 years, see Figure 2 (3). Apart from an increase in risk factors for AF and a 
demographic shift, the incidence increase might also lead to increased AF awareness 
Figure 2. Projected number of adults with atrial fibrillation in the European Union between 2000 and 
2060. Krijthe BP et al. Projections on the number of individuals with atrial fibrillation in the European 
Union, from 2000 to 2060. European Heart Journal. 2013;34(35):2746-51. Reprinted by permission 
of Oxford University Press
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and more intense pursuit to find new AF (30). The more intensively you look for AF, 
it seems, the more you find, with new AF detected in 16.1% of patients with a 30-day 
event-triggered recorder vs. 3.2% on 24h Holter in the EMBRACE trial (31). 
It is well known that AF is associated with an increase in mortality (4) as well as an 
increased risk for stroke and heart failure (5). Common cardiovascular diseases such 
as hypertension, heart failure, valvular disease, diabetes, obesity and chronic kidney 
failure are concomitant conditions that increase the risk of developing AF and com-
plications of AF. In recent years there has been a growing interest in the association 
between AF and cognitive decline, higher risk of dementia (32) and impaired quality 
of life (33). The health care burden of AF is already considerable with frequent 
hospitalisations of AF patients (34). The care of AF patients accounts for about 708 
million euros in direct and indirect costs annually in Sweden (35), raising concerns 
that an increase in healthcare expenditures will accompany the predicted amplified 
prevalence.
Early diagnosis, prevention and treatment of AF along with stroke risk assessment, 
prevention and treatment of concomitant cardiovascular diseases are important fac-
tors in preventing AF and its disease burden in the future (36, 37).
2.2 DIAGNOSTIC CRITERIA AND DEFINITION OF ATRIAL 
FIBRILLATION
For the diagnosis of AF, a rhythm recording using an ECG is required, see Figure 
3. A 12-lead ECG-recording or single-lead ECG recording of at least 30 seconds 
showing the following ECG patterns: Absolute irregular rate-to-rate intervals and 
an absence of normal p-waves confirms AF diagnosis (8). The diagnosis of AF is 
independent of symptomatology. 
During AF, atrial activity might be seen on the ECG, but the atrial complexes, 
termed f-waves, have a different configuration and a variance in distance between 
the different atrial complexes. The atrial rate during atrial fibrillation is >300 per 
minute (6).
Atrial fibrillation is a chronic and usually progressive arrhythmia and seems to fol-
low a “natural time course” in most cases, see Figure 4 (38). Commonly AF pro-
Figure 3. An ECG rhythm recording showing atrial fibrillation
6
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gresses from short and infrequent episodes to more permanent forms over time, but 
the progression to permanent forms of AF is low in young and healthy individuals 
(39).Based on presentation, duration and type of termination, AF is classified into 
five different groups: first diagnosed, paroxysmal, persistent, long-standing per-
sistent and permanent (8). 
• First diagnosed AF –AF not diagnosed before irrespective of duration, pres-
ence or severity of symptoms.
• Paroxysmal AF – AF that terminates spontaneously or with intervention within 
7 days. In many cases termination occurs within 48 hours.
• Persistent AF – AF that is continuously sustained for more than 7 days and/or 
if medical or direct current cardioversion is performed to restore sinus rhythm 
after ≥7 days.
• Long-standing persistent AF – when AF lasts for more than one year, and the 
aim is a rhythm control strategy. 
• Permanent AF – AF that is accepted by the patient and physician and no fur-
ther attempts to restore/maintain sinus rhythm.
2.3 HOLISTIC AND MULTIDISCIPLINARY CARE OF ATRIAL 
FIBRILLATION PATIENTS 
The 2020 ESC AF Guidelines stress the importance of integrated AF patient man-
agement, with the patient at the center (8). The ABC pathway has been proposed as 
a way to streamline integrated care for AF patients, where the A stands for “avoid 
stroke”, the B for “Better symptom management” and the C for “Cardiovascular 
and comorbidity risk reduction”, see Figure 5 (41). The ABC pathway creates a 
simple path for clinicians of different specialties to follow in their management of 
AF patients and has been shown to lower cardiovascular events compared to usual 
care (42, 43).
Figure 4. “Natural time course of AF” Kirchhof P et al. Outcome parameters for trials in atrial fibril-
lation: recommendations from a consensus conference organised by the German Atrial Fibrillation 
Competence NETwork and the European Heart Rhythm Association. Europace. 2007;9(11):1006-
23. Reprinted by permission of Oxford University Press
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2.4 STROKE RISK AND ORAL ANTICOAGULANT TREAT-
MENT IN ATRIAL FIBRILLATION PATIENTS
The increased stroke-risk in AF patients has long been established (6). Age, sex and 
comorbidities of the patient are combined in the widely used CHA2DS2-VASc score 
that predicts those at high risk for stroke (44) and is used in treatment guidance, 
shown in Table 1. 
As any clinical risk-factor-based score, CHA2DS2-VASc performs only modestly 
in predicting high-risk patients who will sustain thrombo-embolic events, but those 
identified as low-risk (CHA2DS2-VASc 0 (males), or score of 1 (females)) consis-
tently have low ischaemic stroke or mortality rates (<1%/year) and do not need any 
stroke prevention treatment. Stroke prevention should be considered in all patients 
with CHA2DS2-VASc of 1 if male, or score of 2 if female and is recommended in 
patients with CHA2DS2-VASc of 2 if male, or score of 3 if female (8). Modifiable 
Figure 5. The ABC pathway: an integrated approach to improve AF management Lip GYH. The 
ABC pathway: an integrated approach to improve AF management. Nature reviews Cardiology. 
2017;14(11):627-8. Reprinted by permission of Springer Nature
Risk factors for stroke Score awarded







Table 1. The CHA2DS2-VASc score used for assessing the stroke risk in AF patients. TIA indicates 
transient ischaemic attack. Adapted from Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refin-
ing clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a 
novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-
72
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bleeding risk factors should be addressed and a HAS-BLED score calculated to flag 
up the patient for regular review (45), see Table 2.
The ABC (Age, Biomarkers, Clinical history) stroke risk score is another, more 
recent, instrument that combines biomarkers with clinical history and has performed 
better in studies than the CHA2DS2-VASc score (46). The ABC stroke risk score 
nomogram is shown in Figure 6. 
Risk factors and definitions Points awarded
H Uncontrolled hypertension (>160mmHg) 1
A Abnormal renal and/or hepatic function
(Dialysis, transplant, serum creatinine>200mcmol/L, cirrhosis, biliru-
bin>2x upper limit, AST/ALP/ALT>3x upper limit)
1 point for each
S Stroke (previous ischaemic or haemorrhagic stroke) 1 
B Bleeding history or predisposition (major haemorrhage, anaemia or 
sever thrombocytopenia)
1 
L Labile INR (TTR <60% in patient receiving VKA) 1
E Elderly (>65 years or extreme frailty) 1
D Drugs or excessive alcohol consumption 1 point each
Table 2. The HAS-BLED risk score for bleeding. Adapted from Pisters R, Lane DA, Nieuwlaat R, de 
Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major 
bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093_1100.
Figure 6. Nomogram for the ACB stroke risk score. Hijazi Z et al. The ABC (age, biomarkers, clini-
cal history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. 
European Heart Journal. 2016;37(20):1582-90. Reprinted by permission of Oxford University Press
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More recent studies concentrate on whether factors such as AF duration, burden, 
type and subclinical AF (AF diagnosed with an opportune ECG in asymptomatic 
patients) affect stroke-risk in such a way that would change generally recommended 
anticoagulant treatment recommendations. 
The highest risk of stroke and death is found in patients with non-paroxysmal AF 
(47). Device-detected subclinical AF is common, and any event of subclinical AF >6 
minutes increases the annual risk of stroke or peripheral emboli by a factor of 2.5 
(48). In patients with paroxysmal AF it seems that the greater the burden of AF the 
greater the risk of stroke (49).
OAC treatment has been shown to reduce ischaemic stroke by at least two thirds 
and to reduce mortality in AF patients (14). The CHA2DS2-VASc score has been 
widely used to guide OAC treatment since it was included in the 2010 ESC AF 
Guidelines (50). 
Vitamin K antagonists (VKA), such as warfarin, were the first anticoagulants used 
in the attempt to reduce stroke risk in AF patients and are still first choice in patients 
with AF with rheumatic mitral valve disease or mechanical heart valves (51). In 
the last 10 years, however, the use of Non-vitamin K antagonist oral anticoagulants 
(NOACs) has been rapidly increasing (52). This is in accordance with evidence sup-
porting efficacy and safety of the NOACs compared to warfarin (53). 
With OAC treatment comes increased risk of bleeding. There are several bleeding 
scores that can be used similarly to the CHA2DS2-VASc score to assess the risk of 
bleeding in patients (45, 54, 55) but the same risk factors that predict stroke are often 
also the ones that predict bleeding. The 2020 ESC AF Guidelines recommended 
calculating a HAS-BLED score and to address modifiable bleeding risk factors to 
flag the patient for a more regular review, instead of withholding OAC treatment (8). 
Treating modifiable bleeding risk factors such as uncontrolled hypertension, alcohol 
abuse, anaemia etc. is recommended.
2.5 RISKS AND SYMPTOMS RELATED TO ATRIAL FIBRIL-
LATION 
AF is a leading cause of morbidity and mortality worldwide (6, 56) with death, 
stroke and heart failure (5) being the most feared complications. In world-wide 
cohort study that  included 15,400 patients from 47 countries, it was shown that 11% 
of patients presenting with AF to the emergency department died within one year, 
mostly from heart failure, but also from stroke (5). 
Heart failure and AF are closely related by their shared pathophysiology and can 
both cause and exacerbate each other (57, 58). Heart failure is the leading cause of 
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death in AF patients (5) and as such is an important disease to prevent, find and treat 
in AF patients.
In patients with AF, there is evidence associated with smaller brain volume (59), 
accelerated cognitive decline and higher risk of dementia (33, 60) even without his-
tory of stroke, a risk which is higher without OAC treatment (61). The 2020 ESC 
AF Guidelines summarise the clinical presentation of AF and AF-related outcomes 
in Figure 7.
Figure 7. Clinical features of AF and AF-related outcomes. European Heart Journal 2020 Aug 29; 
ehaa612.doi:10.1093/eurheartj/ehaa612. Online ahead of print. Reprinted by permission of Oxford 
University Press
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Symptoms are an important factor in both AF diagnosis and treatment and are often 
the reason patients seek medical attention (62). Palpitations are the most common 
symptom reported (63). The true prevalence of asymptomatic AF is, of course, 
unknown, but studies have found a range somewhere between 10-35% of patients 
with AF that are asymptomatic (63, 64). Regardless of symptoms the risk of AF-re-
lated mortality and morbidity is high (28). In patients with incidentally detected 
AF, the use of OAC has been shown to reduce mortality and morbidity (11). Most 
patients with AF are symptomatic, with as high as 16.5% having severe or disabling 
symptoms and a modified European Hearth Rhythm Association (EHRA) score 3-4 
(see Table 3). This is strongly correlated with impaired quality of life in those patients 
(65). Both AF symptoms and quality of life were associated with a higher risk of 
hospitalisations (65). The modified EHRA symptom scale has been recommended to 
be used to guide symptom-oriented treatment options (66), shown in Table 3.
Modified EHRA score Symptomst Description
1 None AF does not cause any symptoms
2a Mild Normal daily activity not affected by symptoms related to AF
2b Moderate Normal daily activity not affected by symptoms related to AF, 
but patient troubled by symptoms
3 Severe Normal daily activity affected by symptoms related to AF
4 Disabling Normal daily activity discontinued
Table 3. The modified EHRA score used for assessing if patients are functionally affected by their 
AF symptoms. Adapted from Wynn et al, The European Heart Rhythm Association symptom clas-
sification for atrial fibrillation: validation and improvement through a simple modification, Europace 
2014;16(7): 965-72
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2.6 SCREENING FOR ATRIAL FIBRILLATION 
AF fulfills most of the WHO’s criteria for population screening (15), see Table 4. 
Wilson and Jungner published their Principles and practice of mass screening for 
disease more than fifty years ago and this is still considered the gold standard for 
screening programs around the world. Wilson and Jungner proposed 10 principles 
that were to serve as a guide for planned screening.
Screening for AF and initiation of OAC therapy could potentially prevent stroke 
from AF in high-risk patients, but the optimal screening program and strategies are 
not yet defined. Studies with hard endpoints are awaited. ECG-screening is costly 
and therefore clinical risk-factors and risk scores such as the CHA2DS2-VASc score 
have been used to identify high-risk patients in screening studies, for example the 
STROKESTOP I study, where the screening resulted in a 30% increase in prevalence 
of AF in participants with CHA2DS2-VASc≥ 2 (10). 
The 2020 ESC AF guidelines recommend opportunistic screening for AF in indi-
viduals >65 years of age with a class I, evidence level B (8). This is mainly based on 
the dominance (better performance and cheaper) of opportunistic screening versus 
systematic screening in the SAFE study from 2005 (67). The opportunistic screening 
methods recommended by the guidelines is by pulse palpation or an ECG rhythm 
strip. They also give a class I recommendation for short term-ECG recording fol-
lowed by continuous ECG monitoring for at least 72 hours in patients with transient 
ischaemic attack (TIA) or ischaemic stroke and regular interrogation of pacemak-
ers and implantable cardioverter defibrillators (ICD) for atrial high-rate episodes 
Wilson and Jungners principles of screening
• The condition sought should be an important health problem
• The natural history of the condition, including development from latent to declared disease, should 
be adequately understood
• There should be a recognisable latent or early symptomatic stage
• There should be a suitable test or examination
• The test should be acceptable to the population
• There should be an agreed policy on whom to treat as patients
• There should be an accepted treatment for patients with recognised disease
• Facilities for diagnosis and treatment should be available
• The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be eco-
nomically balanced in relation to possible expenditure on medical care as a whole
• Case-finding should be a continuing process and not a “once and for all” project
Table 4. Wilson and Jungner’s 10 principles that should be considered when making a screening 
decision. Adapted from Wilson JM, Jungner YG. [Principles and practice of mass screening for dis-
ease]. Boletin de la Oficina Sanitaria Panamericana Pan American Sanitary Bureau. 1968;65(4):281-
393
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(AHRE), which are associated with an increased risk of overt AF (68). 
Although both opportunistic and systematic screening are more effective in diag-
nosing AF than routine practice, the cost of systematic screening is higher, which 
influences the overall gain for society (69). The 2020 ESC AF guidelines give a class 
IIa, evidence level B indication (should be considered) for systematic screening for 
AF in individuals >75 years of age or those at high risk (8). Two Swedish trials on 
systematic screening for AF in 75-year-olds found 5.2% and 3% respectively of the 
screened individuals to have new AF (10, 70). The participants all had a CHA2DS2-
VASc score ≥ 2 making them eligible for OAC treatment.
Finding the optimal screening population is an ongoing quest. A study using a 
computer simulation model based on the STROKESTOP I study and scientific litera-
ture found that the optimal screening age was 75 years with the lowest cost per qual-
ity adjusted life year (QALY) gained (71). Whether screening programs can reduce 
stroke and mortality remains an unanswered question. Several large randomised 
controlled AF screening studies are ongoing-including the STROKESTOP studies, 
SAFER, GUARD AF and LOOP studies-that will help answer that question (10, 
72-75). One publication from 2018 presenting a five-year follow-up of participants 
in a systematic AF screening study in Sweden showed that stroke was indeed sig-
nificantly reduced in the intervention area compared to the control area in a post-hoc 
population-based study (17). US Preventive Services Task Force (USPSTF) does not 
recommend screening for AF because it considers current evidence insufficient (76). 
Whether or not screening for AF is cost-effective has also been studied. The results 
from the SAFE study (67) suggested opportunistic screening of men and women >65 
years of age was cost-effective. A more recent study from the Netherlands where sys-
tematic screening was done in >65-year-olds at the same time as they were receiving 
seasonal influenza vaccination indicated that this would be cost-effective and could 
be implemented in primary care (77). 
A meta-analysis (25 AF screening studies from 14 countries between 2002 and 
2015) on the effectiveness of screening for AF found that active screening among 
individuals 40 years and older was effective and that the organisation of the screen-
ing seemed to be more important than the modalities used for rhythm detection (78).
Screening identifies new AF cases, but designing an ideal screening program is 
complex. For screening to be considered effective it has to combine: 1) choosing 
individuals that might benefit from screening, 2) using safe, convenient and easily 
applied screening tools for participants and personnel and 3) having a reliable, pre-
cise and validated screening modality at the right cost. 
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2.7 SCREENING MODALITIES
Methods for recording ECG have come a long way since Einthoven’s second model 
was manufactured by Cambridge Scientific Instrument Company in the year 1911, 
see Figure 8a. Today’s techniques allow ECG recording by easy wearables, see 
example in Figure 8b.
Over the last few years, heart rhythm detection technology has accelerated and 
numerous new methods of detecting AF have emerged, ranging from automated 
oscillometric blood pressure devices, photopletysmographic (PPG)-based smart-
phone applications to implantable leadless cardiac monitors (79). A summary of the 
most common methods is presented in the latest ESC AF Guidelines, see Figure 9 
(8). When irregular pulse is detected by a screening tool, a 12-lead ECG or a rhythm 
strip of at least 30 seconds interpreted by a physician accustomed to analysing ECG 
rhythm is necessary for establishing an AF diagnosis (8). The methods can hence be 
divided into those requiring an ECG for confirmation and those that do not.
2.7.1 Methods needing ECG confirmation
Pulse palpation is unarguably the cheapest screening tool for AF. It has to be seen as 
a triage test because it needs to be followed by an ECG for confirmation of AF diag-
nosis, which again influences the actual costs of this screening method. A meta-anal-
ysis from 2016 by Taggar et al. in which pulse palpation was compared to blood 
pressure monitors (BPM), non-12-lead ECGs and smartphone applications found 
pulse palpation to have the lowest diagnostic accuracy of identifying AF with a sen-
sitivity of 0.92 and specificity of 0.82 (80). When laymen were asked to palpate their 
radial pulse and then directly perform a 30-second single-lead ECG, the sensitivity 
was merely 25% per measurement occasion (20). 
Figure 8a. Einthoven’s second ECG model Reprinted 
by permission of Oxford University Press
Figure 8b. Wearable ECG reprinted by 
permission of Helge Brandberg
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Figure 9. Systems used for AF screening. European Heart Journal 2020 Aug 29; ehaa612.
doi:10.1093/eurheartj/ehaa612. Online ahead of print Reprinted by permission of Oxford University 
Press. Reprinted by permission of Oxford University Press
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Blood pressure devices can also give an indication of irregular pulse. A study on 
automated oscillometric BPM Microlife WatchBP Home showed a reasonable sen-
sitivity of 80.6% and a high negative predictive value of 99.8% (81). The same 
meta-analysis from Taggar et al. comparing pulse palpation to BPM found BPM 
from the six studies included to have sensitivity of 98% and a specificity of 92%, 
making it more accurate than pulse palpation (80).
Smartphone camera-and PPG-based application Cardio Rhythm had higher sensi-
tivity (92.2%), similar specificity (97.7%), lower positive predictive value (53.1%) 
and similar negative predictive value (99.8%) for AF detection when compared to 
the single-lead ECG by AliveCor (82).
2.7.2 Methods not needing ECG confirmation
There are several ECG rhythm-recording methods available that do not need a 
12-lead ECG registration for AF diagnosis. These vary in time range of heart rhythm 
assessment from intermittent to more continuous and from handheld or mobile 
devices to invasive monitoring devices.
2.7.2.1 Intermittent ECG recording devices
Atrial fibrillation, especially in patients with new onset, is usually paroxysmal and 
short in duration and as a result has often terminated by the time a stand¬ard elec-
trocardiogram is acquired. To overcome this limi¬tation several types of ambulatory 
ECG recording devices have been developed. MyDiagnostick and the Zenicor ECG 
are one-lead handheld devices for intermittent ECG recordings that have been shown 
to be feasible methods for AF screening (10, 83), see Figure 10. The automatic algo-
rithm used by the Zenicor device has been shown to be safe in AF screening, with 
sensitivity of 97.8% on ECG level, 100% sensitivity on individual level and a neg-
ative predictive value of 99.9%(84). AliveCor KardiaMobile is a smartphone-based 
device that records a single-lead ECG than was shown to be better in finding AF 
when performed twice weekly for a year when compared to routine care (85), see 
Figure 11.  
Figure 10. Examples of intermittent handheld ECG devices. Reprinted by permission of a) Zenicor, 
b) Mydiagnostick and c) AliveCor KardiaMobile
a b c
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2.7.2.2 Continuous ECG monitoring devices
There are many non-invasive continuous monitoring devices available. The tradi-
tional Holter monitors are widely used throughout the world, usually with moni-
toring time between 24-72 hours, using 3-7 ECG leads. A more recent evolution 
of continuous monitoring is the ECG patch, a cutaneous patch that continuously 
records a single-lead ECG for up to 14 days, see Figure 11. In a pilot study compar-
ing the standard-care of 24-hour Holter monitoring to the Zio Patch, the Zio Patch 
identified 58% more new AF cases as a consequence of the extended ECG recording 
duration. The device was well tolerated by the participants (86). The Zio Patch along 
with two other modern continuous monitors, the Carnation Ambulatory monitor and 
the Nuubo vest, were compared to the traditional event-recorder Novacors R-test 
in participants with implanted pacemakers. All three were more accurate than the 
R-test (87). A simulation study recently published in which the Zio patch was used as 
a continuous ECG monitor, and 350,000 computer simulations estimated screening 
strategies involving intermittent ECG of any frequencies and duration up to14 days. 
The study found that an intermittent screening protocol of twice daily screenings for 
14 days would have detected about 52% of individuals with AF in an asymptom-
atic population compared to continuous ECG monitoring. Increasing the screening 
protocol to four times daily would have identified 66% of the individuals with new 
AF (88). Such simulation studies can help in designing the optimal AF screening 
program.
Figure 11. Non-invasive continuous monitoring, the Zio patch. Reprinted by permission of Irhythm 
technologies
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Invasive monitoring devices, so-called implantable loop recorders (ILR) or implant-
able cardiac monitors (ICM) are implanted subcutaneously to continuously monitor 
arrhythmias. The newer ones have AF algorithms and have been studied in cryp-
togenic stroke patients, one of those being the CRYSTAL-AF study which found 
9% of the stroke patients with AF after 6 months in the ILR group compared to the 
1% found in the routine care group (89). The ASSERT II trial used ICM to study to 
what extent subclinical AF was present in older people (>65 years) and found that 
subclinical AF > 5 minutes occurred at an incidence rate of 34.4% per person year 
(90). In the recently published LOOP study in which >70-year-olds with at least one 
additional risk factor according to the CHA2DS2-VASc score had an ILR implanted, 
the cumulated incidence at 3 years for AF >6 minutes was 33.8%. 
The STROKESTOP study (NCT01593553), LOOP study (NCT02036450), 
STROKESTOP II study (NCT02743416), GUARD-AF (NCT04126486) and 
SAFER (ISRCTN16939438) study are all ongoing, randomised controlled studies, 
that will evaluate whether the applications of newer devices in selected clinical sce-
narios will improve clinical outcomes.
2.8 BIOMARKERS IN ATRIAL FIBRILLATION
Several plasma biomarkers have been proposed as possible aids in diagnosing AF 
and also in predicting AF related mortality and morbidity (91). Different biomark-
ers representing various pathophysiological pathways such as inflammation (IL-6, 
CRP), myocyte damage (troponin I and T), atrial dilatation or increased wall stress 
(natriuretic peptides) and altered haemodynamics (GFR, cystatin-C) have been stud-
ied, to name a few (91). Structural remodelling of the atria with fibrosis and con-
nective tissue deposition (92) causes electrical dissociation between muscle bundles 
(93) and atrial conduction abnormalities which, in turn, become a substrate for AF. 
This structural remodelling can be caused by conditions such as hypertension, coro-
nary artery disease and heart failure, among others (94), as well as atrial fibrillation 
itself (95) and is partially reversible when the underlying disease is treated (96).  
N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is a well-known marker 
for heart failure (97). It is excreted in response to dilatation and increased pres-
sure and volume in the heart (98). NT-proBNP is also the best-studied biomarker in 
patients with AF and the most recognised one to predict incident AF, see Figure 12 
(99, 100). It has also been shown to be associated with increased risk of stroke and 
mortality in AF patients (19) and it was included along with Troponin T in the ABC 
stroke risk score, which performed better than the most commonly used clinically 
based risk score (46).
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Clinical risk scores offer a modest predictive value of thromboembolic event with 
C-statistic that range from 0.549 to 0.638 (44). A subanalysis of the ENGAGE-
AF-TIMI 48 trial showed that the biomarkers NT-proBNP, Troponin I and D-di-
mer, when added to the CHA2DS2-VASc score, improved the prognostic accuracy 
with a C-statistic increasing significantly from 0.586 to 0.708. After adjusting for 
CHA2DS2-VASc score, each biomarker had a remaining 2.8 to 4.2-fold increased 
risk for stroke, systemic embolic event or death (101).
A study using data-driven analysis of 40 cardiovascular biomarkers and clinical 
risk factors to fit a model for predicting AF found three biomarkers to be associ-
ated with AF: increased brain natriuretic peptide (BNP), increased fibroblast growth 
factor 23 (FGF-23) and a reduced TNF-related apoptosis-induced ligand-receptor 
2 (TRAIL-R2)(102). Further studies on biomarkers are needed to find the optimal 
marker, which might differ for prediction of AF and outcomes such as stroke, death 
and/or major complications to OAC treatment. This could potentially form the basis 
of a more precise and personalised treatment. 
2.9 SCREENING PARTICIPATION
The success of any screening program is dependent on the participation in the pro-
gram. In a Swedish AF screening study the non-participants had significantly higher 
stroke risk (22). In the SAFE study, participants <75 years were more likely to 
Figure 12. Nagata T et al. Serum N-terminal pro-B-type natriuretic peptide as a predictor for future 
development of atrial fibrillation in a general population: the Hisayama Study. International Journal 
of Cardiology. 2020. 10.1016/j.ijcard.2020.06.018. Published by permission of Elsevier
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attend, but AF was more likely to be detected in those >75 years (67), showing that 
participation is lower for those at highest risk for both AF and its complications. In 
the STROKESTOP I study, socioeconomic factors such as education level, marital 
status, income level and immigrant background had significant impact on the partici-
pation. The distance to the screening centre also had an impact on participation, with 
higher participation for participants living closer to the screening centre (103). In 
the VIVA study, a Danish screening study for abdominal aortic aneurysm, peripheral 
arterial disease and hypertension, specially trained nurses operated mobile clinics 
which surely aided its screening uptake of 74.7% (104). Similarly, in a Norwegian 
study on the prevalence of AF and use of OAC treatment that offered home visits 
to disabled patients, participation was 82% (105). Even when the screening is part 
of a known and established screening program such as for breast cancer, screening 
uptake decreased with increasing socioeconomic deprivation and travel distance 
(106). How to best lower this socioeconomic gradient and to include in screenings 
those that require it the most is a complicated question likely with a multifaceted and 
non-homogenous answer.
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3 AIMS
The main aim was to study different factors affecting the outcome of systematic 
population screening for atrial fibrillation in risk patients. These factors included 
the biomarker NT-proBNP, pulse palpation, socioeconomic, geographic and medical 
history disparities in participants and non-participants. 
STUDY I
The aim was to study AF detection and predictors for new AF using NT-proBNP in 
a stepwise screening study in a high-risk population, as well as to study OAC treat-
ment uptake and one-year adherence in those diagnosed with new AF.
STUDY II
The aim was to study detection of new AF using pulse palpation compared to one-
lead ECG and to study if symptoms of palpitations were associated with the AF yield 
among participants.
STUDY III
The aim was to analyse geographic and sociodemographic disparities in the uptake 
of the STROKESTOP II study and compare the results between STROKESTOP I 
and STROKESTOP II after adding two new screening sites in STROKESTOP II.
STUDY IV
The aim was to study the potential yield of detected disease in non-participants and 
to compare characteristics of non-participants and participants in an atrial fibrillation 
study.
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4 MATERIALS AND METHODS 
4.1 STUDY POPULATION
All individuals born in 1940 and 1941 (n=28,712), residing in the Stockholm region 
were identified by Statistic Sweden using their 12-digit personal civic identifica-
tion number, which is given to every permanent resident in Sweden upon birth or 
immigration for life-long use. After stratification for gender and age, a 1:1 rando-
misation provided an intervention group and a control group. The study population 
for studies I-IV was the intervention group (n=14 356) invited to participate in the 
STROKESTOP II, a population-based cohort study on AF screening. The control 
group underwent no intervention and were followed-up in registries. After controls 
of vital status, the intervention group was invited to screening by mail to whichever 
one of three AF screening clinics that was closest to their home residence. Partici-
pants were asked to self-report their medical history regarding prior AF diagnosis, 
OAC treatment, thromboembolic risk factors according to CHA2DS2-VASc score, 
pacemaker treatment, palpitation symptoms, weight and height. There were no inclu-
sion criteria other than year of birth and home residence in the Stockholm region for 
those in the intervention group and no exclusion criteria. The intention-to-screen 
arm comprised 14,356 individuals, see Figure 13. Data for participants was collected 
between April 2016 and February 2018. 
Figure 13. STROKESTOP II Study flow chart
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4.2 STUDY I
Study I was a prospective cohort study on AF detection in 75-year-olds using 
NT-proBNP and intermittent single-lead ECG. At the screening sites, all participants 
without previous AF had NT-proBNP analysed from venous blood samples using 
point-of-care analysis (Cobas h 232, Roche diagnostics, Rotkreutz, Switzerland) 
(107). Participants were stratified into two groups based on their NT-proBNP result. 
Participants were in the low-risk group if NT-proBNP <125 ng/L and in the high-risk 
group if NT-proBNP ≥125 ng/L. These cut-off values had been defined based on a 
sub-study to the STROKESTOP I study (108) to select the individuals with high-
est risk for AF. All participants without previous AF recorded an index single-lead 
ECG consisting of a 30-second rhythm strip using the handheld Zenicor ECG device 
(Zenicor Medical Systems, Stockholm, Sweden). Individuals in the high-risk group 
continued with prolonged ECG screening using the Zenicor ECG device four times 
daily-at morning, noon, afternoon and evening-for two weeks. Individuals in the 
low-risk group underwent no further ECG investigation if their index ECG revealed 
sinus rhythm. 
No ECG or further examination was performed in participants with previously 
known AF but if they did not have OAC treatment they were referred to cardiologist 
for assessment, as all participants received two points on the CHA2DS2-VASc scale 
based on their age alone. Participants with NT-proBNP ≥900 ng/L and no previous 
diagnosis of heart failure were referred to a cardiologist for echocardiography and 
assessment in addition to the ECG screening. In case of new AF diagnosis during 
the screening procedure, participants were referred to a cardiologist for a standard 
follow-up during which OAC treatment was initiated unless contraindicated. Blood 
pressure (BP) was measured in all participants and if it was >140/90 and no known 
diagnosis of hypertension, they were referred for further control to their general 
practitioner or a cardiologist. 
4.2.1 Outcome measures
Atrial fibrillation was defined as a completely irregular rhythm with no organised or 
regular atrial activity of 30 seconds duration on single-lead ECG. Participants with 
AF diagnosed using handheld ECG did not undergo any additional ECG investiga-
tion. Initiation of OAC treatment was defined as an issued OAC prescription after a 
cardiologist visit and adherence to treatment at one-year follow-up.
4.2.2 Diagnostic modalities 
The Zenicor ECG device, see Figure 14, records a 30-second ECG in lead I and 
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automatically transmits the encrypted recording to a password protected database. 
The Zenicor ECG device has been extensively validated and used in several previous 
AF screening studies (10, 109).
A validated computerised algorithm was used to identify ECG recordings with 
sinus rhythm or minor artefacts (84). These recordings were not systematically man-
ually interpreted, but a random sample was inspected by cardiologists throughout the 
inclusion period. All ECGs identified by the algorithm as abnormal were manually 
interpreted by arrhythmia trained nurses and subsequently, all pathological ECGs 
were scrutinised by the study team cardiologists. Participants with insufficient signal 
quality (less than 50% of recordings interpretable) on handheld ECG or possible 
positive finding like atrial flutter (which can be difficult to interpret on a single-lead 
ECG) were offered a 5-day Holter recording. The medical records of participants 
with pacemaker treatment were studied for atrial high-rate episodes with a duration 
of at least six minutes and available device electrograms. 
4.2.3 Statistics
Baseline characteristics including age, sex, height, weight and previous medical 
history according to CHA2DS2-VASc were summarised using frequencies for cate-
gorical variables and means with standard deviation (SD) for continuous variables. 
For CHA2DS2-VASc and NT-proBNP both mean (SD) and median with 25
th and 
75th centiles were calculated. The following tests were used for differences among 
groups: The Chi2 test was used for categorical variables; students T-test was used 
for height and weight; and Mann-Whitney U test was used for CHA2DS2-VASc and 
NT-proBNP, which showed a skewed distribution. The relations between clinical 
variables and logarithmically transformed NT-proBNP with new AF were investi-
gated in the group with NT-proBNP≥125 ng/L using multivariable logistic regres-
sion. A probability value of < 0.05 was regarded as significant. Analyses were per-
Figure 14. Handheld single-lead ECG – Image courtesy of Zenicor
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formed using STATA/MP 15.1 (StataCorp, 4905 Lakeway Drive College Station, 
TX77845, USA).
4.3 STUDY II
Study II was a diagnostic accuracy study that compared the yield of AF detection 
between pulse palpation and single-lead ECG.
4.3.1 Outcome measures
Irregular pulse was considered to be a positive test and recorded as such in the eCRF 
form.
AF was defined as irregular rhythm with no organised or regular atrial activity for 
30 seconds on single-lead ECG or on a 12-lead ECG.
History of palpitations were noted in the eCRF as a binary yes/no variable to the 
question “Do you have palpitations?”.
4.3.2 Diagnostic modalities
Trained healthcare professionals performed pulse palpation of the radial pulse for 30 
sec in all participants in the STROKESTOP II study without previously known AF, 
see Figure 15. Regular pulse was defined as regular in rhythm and force. The pattern 
of irregularity was not especially defined. Directly following the pulse palpation, 
a 30-sec handheld single-lead ECG recording with the Zenicor ECG device was 
obtained and evaluated by the same health care professionals. 
The ECG analysis with Zenicor ECG device used a computerised algorithm mark-
ing all ECGs with sinus rhythm as normal. ECGs with minor artefacts, poor signal 
quality or possible AF or another arrhythmia were flagged by the algorithm as abnor-
mal. The algorithm has been extensively validated, showing a 100% sensitivity of 
the system in identifying AF on an individual level and a negative predictive value 
of 99.99 % (84). If the algorithm classified a recording as sinus rhythm and this was 
agreed upon by the study nurse, a 12-lead ECG was not deemed necessary. If the 
algorithm indicated AF, artefacts or if the signal quality was too poor for interpreta-
tion, a 12-lead ECG was obtained, and one of the cardiologists from the study team 
was contacted for interpretation. 
The results from the single-lead ECG (and/or 12-lead ECG when deemed nec-
essary) was used as reference standard in accordance to recent guidelines for AF 
diagnosis (8). Post hoc, all index single-lead ECGs were scrutinised by three car-
diologists to confirm whether sinus rhythm could be clearly identified or whether 
a 12-lead ECG should have been taken at the time. A sensitivity analysis was per-
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formed including participants from whom a 12-lead ECG had not been obtained and 
results from two weeks of intermittent single-lead screening following the index 
visit were imputed as a result. Participants that had not concluded the additional 2 
weeks of screening were excluded from the sensitivity analysis.
Participants were asked to answer the yes/no question “Do you have palpitations?” 
in a questionnaire before the visit. There was no request for a specification of char-
acter, duration or temporal context of palpitation symptoms. 
4.3.3 Statistics
Based on previous studies on pulse palpation, for reliable sensitivity and specificity, 
we needed at least 4,984 participants to achieve 80 % power to show significant 
difference between the two screening tests (80).
Categorical variables were expressed as numbers and percentages. The demo-
graphics of individuals with and without new AF were compared using the Pearson’s 
chi-squared test for categorical variables. 
Diagnostic accuracy parameters of the screening test were derived from a 2x2 
contingency table. We reported the number of true positives, true negatives, false 
positives and false negatives. We calculated sensitivity and specificity, accuracy, 
positive and negative predictive values, likelihood ratios as well as the post-test 
predictive values. Diagnostic accuracy parameters were expressed as means with 
95% confidence intervals. We conducted subgroup analyses on the accuracy of the 
screening test for symptomatic vs. asymptomatic participants and compared their 
area under the curve. 
McNemar’s test for dependent proportions was used to test whether the pulse pal-
pation test was equivalent to the handheld-ECG test. For all statistical comparisons, 
Figure 15. A demonstration of the radial pulse palpation
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a p-value < 0.05 was considered significant. 
We reported the results of this study according to the Standards for Reporting 
of Diagnostic Accuracy Studies (STARD) statement. All analyses were performed 
using STATA/MP 15.1(StataCorp, 4905 Lakeway Drive College Station, TX77845, 
USA).
4.4 STUDY III
Study III was a cross-sectional prevalence study on the socio-demographics in the 
cohorts from the STROKESTOP I and II studies. The STROKESTOP I study, also 
a population-based cohort study on 75/76-year-olds in the Stockholm and Halland 
regions, is the first of the STROKESTOP studies (10). In the STROKESTOP I study 
socio-demographic differences of the participants were studied and lower education 
level, lower income level and immigrant status were all associated with lower par-
ticipation (103). These findings were taken into consideration when designing the 
STROKESTOP II study to try to counteract the socioeconomic gradient. Two new 
screening sites were added-the Sodertalje Hospital site and Karolinska University 
Hospital Huddinge site-which were located closer to low-income neighbourhoods 
with a very low participation rate in the STROKESTOP I study, see Figure 16. In 
addition, a website (www.strokestop2.se) was launched for general information on 
AF, the study procedure and the study team. The patient information was translated 
to the nine most common languages in Sweden.
Figure 16. The site used in both STROKESTOP studies (pink pin) and the two new sites (blue and 
green pins) in the STROKESTOP II study
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4.4.1 Data
The STROKESTOP II database comprises information on each invited person’s res-
idential parish (99 parishes in Stockholm). Statistics Sweden provided anonymised 
individual data for both participants and non-participants for each of the following 
socioeconomic variables: educational level, disposable income, immigrant and mar-
ital status. Invited persons who were not possible to classify based on the informa-
tion in the national registers were grouped into an “other/unknown” category of 
the variable at issue. The same socio-demographic variables were considered and 
obtained in the STROKESTOP I study, but individual-level data was not obtained 
on the socio-demographic characteristics. Rather, the data used in STROKESTOP I 
were aggregated at the parish-level.
4.4.2 Statistics
P-values for the null hypothesis of equal participation in men and women and for 
each socioeconomic variable were obtained by Chi-square test. All tests were two-
sided, and a value of p<0.05 was regarded as significant.
Geo-maps of Stockholm county displaying spatially smoothed participation ratios 
were estimated by hierarchical Bayes methods. A parish-specific participation ratio 
(PR) was based on the observed-to-expected participation, where the expected 
number of participants was obtained from the sex-specific rates for the total study 
population of the county. Spatially smoothed participation rates were obtained by 
running the hierarchical Bayesian mapping model (the Besag-York-Mollié model) 
implemented in the Rapid Inquiry Facility program(110). This procedure allows 
parish-specific participation rates to be smoothed towards global and local mean 
participation rate levels across the county, yielding “shrinkage” of the conventional 
observed to expected ratios—in line with principles for multi-level modeling(111). 
The corresponding statistical certainty geo-maps were obtained by calculating the 
posterior probabilities of a PR >1 given the data, denoted Pr (PR>1|data), using 
the Bayesian approach. A parish with data yielding strong statistical evidence of 
elevated participation, more precisely Pr (PR >1|data)> 0.90, was coloured green 
in the certainty geo-map. By contrast, a parish with lowered participation rate, Pr 
(PR< 1|data)> 0.90, was coloured red. The remaining parishes were coloured yellow. 
The choice of 0.90 for identifying an area with elevated/lowered participation rate 
has been shown to provide a cut-off with reasonable sensitivity and high specificity 
(112). 
Binary logistic regression was used for the univariate and multivariable anal-
yses of socio-demographic factors for the outcome reflecting participation or 
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non-participation. 
The statistical computations were performed by using IBM SPSS Statistics for 
Windows, Version 24.0. Armonk, NY: IBM Corp. For the spatial analyses, the Rapid 
Inquiry Facility free software (RIF 3.12).
4.5 STUDY IV
Study IV is an analytical cross-sectional study. The study population was the inten-
tion-to-screen group invited to participate in the STROKESTOP II study.
4.5.1 Data variables
Disease histories of the individuals were identified using data from the National 
Patient Register (NPR) (113). Disease history variables were collected from inpa-
tient (hospitalisations) and outpatient (a visit to the hospital, clinic or associated 
facility for diagnosis and treatment) records from January 1st, 2001 up to the index 
date. Thirty-one disease variables were chosen based on clinical experience. Medical 
conditions were classified as present if the subject had at least one inpatient or out-
patient record during this period. Possibly curable conditions were limited to shorter 
time periods (e.g., cancer was defined as prevalent only if a record occurred within 
3 years proceeding index date). The disease history variables (and ICD-10 codes) 
Disease ICD-10 Codes and procedure codes beginning with
Atrial fibrillation I48
OAC treated atrial fibrillation I48 & ATC Codes beginning with B01
Ischemic stroke I63, I639
Pulmonary embolism (Inpatient only) I26, Z867A
Thromboembolism I63, I64, I693, I694, G45, I74
Intracerebral bleeding I61, I691
Other intracranial bleeding I60, I62, S064, S065, S066, I690, I692
Hospitalization due to bleeding (Inpatient only) I60, I61, I62, S064, S065, S066, I690, I691, I692, 
I850, I983, K226, K250, K252, K254, K256, K260, K262, K264, 
K266, K270, K272, K274, K276, K280, K284, K286, K290, K625, 
K661, K920, K921, K922, N02, R319, N950, N939, N501A, H113, 
H313, H356, H431, H450, H922, I312, J942, M250, R04, R58, 
D500, D629, T810, Z513
Anaemia D5, D60, D61, D62, D63, D64
Myocardial infarction I21, I22, I252
Vascular disease I21, I22, I252, I170, I171, I172, I173
Peripheral artery disease I70, I71, I72, I73
Heart failure I50, I110, I130, I132, I255, K761, I42, I43
Mitral stenosis I342, I050, I052, Q232
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included in the dataset are shown in Table 5.The Swedish prescribed drug registry 
The Swedish prescribed drug registry (114) was used for data on prescription medi-
cine dispensings for participants and non-participants. Based on clinical experience 
13 prescription medicine classes were included in the analysis, see Table 6. Active 
treatment was defined by at least two dispensings of the medicine within 3 years 
Table 5. Data variables and their ICD-10 codes included in the dataset.




Parkinson's disease medications N04
COPD medication R03






Lipid lowering agents C10
Table 6. Medical prescription categories included in the dataset.
Mechanical prosthetic valve Z952
Pacemaker Z950, Z450
Hypertension I10, I11, I12, I13, I14, I15
Hyperlipidemia E78
Diabetes E10, E11, E12, E13, E14
Liver disease K70, K71, K72, K73, K74, K75, K76, K77
Chronic kidney disease N18, N19
Hypothyroidism E00, E01, E02, E03, E890
Thyrotoxicosis E05 during previous year before index
Chronic obstructive pulmonary 
disease 
J43, J44
Rheumatoid arthritis M05, M06
Osteoarthritis M15, M16, M17, M18, M19
Alcohol index E224, F10, G312, G721, I426, K292, K70, K860, O354, P043, Q860, 
T51, Y90, Y91, Z502, Z714
Dementia F00, F01, F02, F03, F051, G300, G301, G308, G309
Cancer (last 3 years) C0, C1, C2, C3, C40, C41, C42, C43, C45, C46, C47, C48, C49, C5, 
C6, C7, C8, C9
Parkinson's disease (%) G20, G21, G22, G23, G24, G25, G26
Psychiatric diseases (%) F2, F3, F6
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preceding index date. 
Individuals were classified according to the weighted Charlson’s comorbidity index 
(quantifies the burden of disease and corresponding 1-year individual mortality) 
(115). CHA2DS2-VASc scores were estimated from ICD-10 codes. Multimorbid 
individuals were classified according to the criteria used by the Swedish National 
Board of Health and Welfare (116). For individuals to be considered multimorbid 
they had to fit at least one of the following criteria in the 12-month period prior to 
index date:
• They had to have been hospitalised at least 3 times with a main diagnosis from 
separate ICD-10 chapters.
• They had to have been hospitalised at least 20 days.
• They had to have been hospitalised at least 4 times.
• They had to have had at least 8 outpatient visits. 
Statistics Sweden provided anonymised individual data for both participants and 
non-participants for the following socioeconomic variables: educational level based 
on school level completed (primary, secondary, tertiary), disposable income (low, 
medium, high), immigrant (born in Sweden, born abroad) and marital status (unmar-
ried, married, divorced, widow/widower).
4.5.2 Index dates
Individuals in the intention-to-screen group received up to three invitations to attend 
the screening study. Among participants, the average delay from the last received 
call to their examination was 16 days (SD: 9, Range: 0 to 386). The date of the 
examination was used as the index date for participants, but index dates were not 
available for non-participants. To handle this issue, randomly sampled numbers from 
the empirical distribution of time delays among the participants were used to assign 
hypothetical examination dates to the non-participants. This made it possible to 
relate disease histories and pharmaceutical dispensation patterns to specific periods 
prior to examination uniformly for all individuals in the dataset.
4.5.3 Statistical analysis: predicting participation
A random forest was trained to predict the propensity score for participation. Ran-
dom forests are strong alternatives to parametric models (e.g., logistic regression) in 
the presence of non-linear effects and unforeseen interactions between covariates, 
as they do not require these to be specified in advance. In addition, they can flexi-
bly handle data with many covariates. Specifically, the regression forest algorithm 
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introduced by Athey et al. (117) was applied using the grf package for R (118). 
All variables available for both participants and non-participants were included as 
predictors. Fifty thousand regression trees were grown and parameters that control 
the complexity of the model were tuned (e.g., the minimum number of individu-
als allowed in each group in the regression trees) using the cross-validation feature 
implemented in grf.
4.5.4 Generalization weights: potential screening yield
Out-of-bag predictions from the forest were used to construct inverse probability 
of sampling weights (IPSW) for each participant (119, 120). These weights were 
used to estimate potential screening yield of disease under a hypothetical scenario in 
which everyone participated. In addition, another set of weights was defined to esti-
mate screening yield of disease for non-participants. The potential screening yield 
was measured as estimated proportions of 
• Prior AF
• Unmedicated AF (defined as prior AF and no OAC treatment)
• New AF (screening detected AF)
• Untreated AF (defined as the sum of new AF and unmedicated prior AF)
• Participants’ CHA2DS2-VASc scores as a proxy for patients with high risk for 
stroke if detected with new AF and therefore would probably benefit from 
screening 
When applicable, p-values were estimated with Chi2 test for binary variables (n, 
%), with t-test for continuous variables (mean, SD). Covariate balance checks for 
inverse probability weighting methods were done by plotting standardised differ-
ences for means and proportions for all covariates, shown in Figures 17 and 18. 
The weights were able to improve covariate balance for both target populations; 
the average absolute standardised difference taken over all covariates before and 
after weighting was 0.124 versus 0.06 (52% imbalance reduction) and 0.068 versus 
0.035 (48% imbalance reduction) for the non-participants and intention-to-screen 
population, respectively.
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Figure 17. Covariate balance in the intention-to-screen group
34









Cancer (last 3 years)
Cardiac medications
CHA2DS2−VASc score
Charlson comorbidity index (weighted)
Chronic kidney disease
Chronic obstructive pulmonary disease
COPD medication
Days spent hospitalized last year prior to index
Dementia
Diabetes
Diabetes medications and isulin











Hospitalization due to bleeding
Hospitalizations (t−1 year from index)
Hospitalizations (t−2 years from index)
Hospitalizations (t−3 years from index)
Hospitalizations (t−4 years from index)
Hospitalizations (t−5 years from index)















































Outpatient visits (t−1 year from index)
Outpatient visits (t−2 years from index)
Outpatient visits (t−3 years from index)
Outpatient visits (t−4 years from index)
Outpatient visits (t−5 years from index)












Unique ATC−codes with repeated consumption (last 3 years)
Vascular disease
0.0 0.1 0.2 0.3 0.4





Figure 18. Covariate balance in the non-participants group
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Inverse probability weighting requires overlap in the covariate distributions 
between participants and non-participants, also known as positivity (121). Two 
checks were performed to assess potential violations of the positivity assumption 
(i.e., whether or not there are values of the covariates at which there are no par-
ticipants or non-participants). Firstly, histograms of the distribution of estimated 
propensity scores by participation status were compared (Figure 19), which did not 
show any areas of non-overlap (implying that non-positivity was not an issue) (122). 
Secondly, we checked that stabilized versions of the weights have mean close to one 
(non-participants: [mean: 1.07; SD: 0.67; min: 0.31; max: 7.78]; intention-to-screen: 







0.2 0.4 0.6 0.8








Figure 19. Histograms of the distribution of estimated propensity scores by participation status 
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5 ETHICAL CONSIDERATIONS
All the research projects depended on human participants. The studies complied 
with the Declaration of Helsinki, and the protocol was approved by the regional 
ethics committee in Stockholm (DNR 2015/2079–31/1). All participants received 
oral and written information and signed informed consent documents.
To screen for a disease in individuals free from symptoms can be controversial 
when the treatment offered entails risks, as oral anticoagulation treatment does. The 
potential benefits of preventing stroke appear great, as the costs for stroke are high 
and causes severe suffering for patients. Therefore, it is important to be able to per-
form randomised controlled trials to answer the question if screening does indeed 
benefit patients as well as society. 
The STROKESTOP studies are ongoing prospective trials with the aim of study-
ing whether or not treating screening-detected AF can prevent stroke and death. Our 
participants were all at least 75 years of age and as such were considered to have an 
increased risk of stroke according to the CHA2DS2-VASc score even without any 
other co-morbidities. AF discovered by any other mean would most probably lead to 
a recommendation of OAC treatment. A very recent study found that individuals with 
screening detected AF had significantly higher mortality risk than the individuals 
without AF (16) and observational data suggest that screening-detected AF responds 
in the same way as AF discovered by routine care, thus favouring screening (11). All 
participants with a new AF were referred to a dedicated cardiologist for assessment 
before initiation of OAC treatment in accordance to guidelines. 
As in any screening program, the individuals participating might have worried 
about their results, both positive or negative, or may have felt falsely assured by a 
negative result. This is something that all screening studies have to acknowledge. 
In this case, the possibility to answer the question ‘whether screening can prevent 
stroke and death’ was considered to be of more importance. 
Participation in the studies entailed that the patients submitted blood samples, 
which could have caused some discomfort. Blood pressure was measured, but that 
was considered non-harmful to the participants. The single-lead ECG method was 
non-invasive and did not physically harm the participants, but the high-risk group 
had to record intermittently for two weeks, which could have been of some distur-
bance to their everyday life and routines.
Any participant with an abnormally high NT-proBNP and no previous history of 
heart failure was referred to a cardiologist for echocardiography control and assess-
ment. All participants with abnormally high blood pressure without previous his-
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tory of hypertension were referred to their general practitioner. All participants with 
severe arrhythmia were followed up by a cardiologist as were all participants with 
new AF. 
Studies III and IV were partly register based. We used information from the 
National Patient registry, the Swedish prescribed drug register and Statistics Sweden 
provided socioeconomic data. In these national data bases individuals are not given 
the option to opt-out of registration so there is a substantial amount of sensitive data. 
As the registry sets contain sensitive data, Sweden’s national authorities de-identify 
all data before giving it to researchers. The key to connect the data to participants is 
kept at the Social Board of Health and Welfare for safe keeping. The risk of violating 
individual patients’ integrity within the context of these large sets of anonymised 
data generating aggregated results was considered to be very low.
For the participants the privacy violation was considered exiguous as sensitive 
personal data was collected first after the informed consent was given. The par-
ticipants were invited via mail, where it was stated clearly that participation was 
non-compulsory, and the possibility to withdraw was available. All personal data is 
stored in a safe database provided by Zenicor, and original files are stored according 
to Swedish research data storage recommendations.
38
Katrín Ragna Kemp Guðmundsdóttir
6 RESULTS PER STUDY
6.1 STUDY I
The number of individuals that accepted the invitation to participate in the 
STROKESTOP II study was 6,868 or 49.5% of the intention-to-screen group. Pre-
vious AF was found in 553 (8.1%) participants, out of which 90.2% were on OAC 
treatment. Participants with known AF not on OAC treatment were referred to a 
cardiologist for assessment.
NT-proBNP was analysed in 6,315 participants. Values ≥125 ng/L were found in 
3,766 (59.6%) of the participants, classing them according to our definition as “high-
risk” for atrial fibrillation. These individuals were invited to participate in prolonged 
screening using single-lead ECGs intermittently for two weeks.
6.1.1 AF detection and prediction
All participants performed an index single-lead ECG at the screening visit. In 29 
participants a new diagnosis of AF was made on the index-ECG. All participants 
save one belonged to the high-risk group. The high-risk group performed prolonged 
screening, and in additional 136 individuals were diagnosed with new AF during the 
two weeks of screening. In total, 165 new cases of AF were detected. In the high-risk 
group, the detection rate was 164/3,766 (4.4%, 95% CI 3.7-5.1), see Figure 20. In 
the entire group attending screening, new AF was detected in 165/6,315 (2.6%, 95% 
CI 2.2-3.0) of participants without previously known AF. The screening procedure 
resulted in an almost 30% increase in AF prevalence among participants in total, or 
an absolute increase in AF prevalence from 8.1% to 10.5%. The number of people 
who needed to be screened in this population to find one new case of AF was 38. 
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The 29 participants diagnosed with new AF on their index-ECG had significantly 
higher NT-proBNP than those diagnosed with new AF during the following two 
weeks, with a median NT-proBNP levels of 1,308 ng/L (IQR 663-2,180 ng/L) versus 
305 ng/L (IQR 199-522 ng/L), see Figure 21.
Figure 20. Study flow chart and AF yield in the high-risk group. EP Europace 2020;22(1): 24-32. 
Reprinted by permission of Oxford University Press
Figure 21. NT-proBNP levels in participants with new AF on index-ECG vs. 2weeks screening. EP 
Europace 2020;22(1): 24-32. Reprinted by permission of Oxford University Press.
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The distribution of new AF stratified to NT-proBNP levels and CHA2DS2-VASc 
scores is depicted in Figure 22. The interquartile odds ratio from NT-proBNP quar-
tile 1 to 4 was 4.19 (95%CI 2.54 - 6.93).
NT-proBNP was the strongest predictor in the high-risk group for new AF, see Table 
7.
Figure 22. AF yield in relation to CHA2DS2-VASc score and NT-proBNP quartiles. EP Europace 
2020;22(1): 24-32. Reprinted by permission of Oxford University Press.
Variables OR (95% CI) P-value
Congestive heart failure (yes) 0.85 (0.31-2.33)
Hypertension (yes) 0.97 (0.70-1.36)
Diabetes mellitus (yes) 0.65 (0.37-1.15)
Prior stroke/TIA (yes) 0.83 (0.59-1.16)
Vascular disease (yes) 0.52 (0.27-0.99) 0.047
Gender (female) 0.53 (0.38-0.74) <0.001
BMI (kg/m2) 1.05 (1.01-1.10) 0.011
Log NT-proBNP 3.06 (2.39-3.75) <0.001
Table 7. Multivariable analysis for AF detection in the high-risk group. EP Europace 2020;22(1): 24-
32. Reprinted by permission of Oxford University Press.
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6.1.2 Use and initiation of oral anticoagulants
Of the 165 participants with new AF, 94.5% were initiated on OAC treatment after 
cardiologist assessment. Of those with previously known AF, a majority (90.2%) 
were on OAC treatment. Participants with previously known AF but not on OAC 
treatment were referred to a cardiologist for assessment. Not all of them accepted the 
referral but of those that did accept, 70.5% were initiated on OAC treatment. At one-
year follow-up, 96% of the patients initiated on OAC treatment were still adherent 
to the treatment. In total 219/6,868 (3.2%) participants were diagnosed with new or 
previously untreated AF, thus making them eligible for OAC therapy. 
None of the patients were referred for electrical cardioversion nor ablation at their 
initial cardiologist assessment. Pacemaker was implanted in four patients due to 
high degree AV-block on prolonged holter recording, and two were referred for left 
atrial appendage occlusion because of OAC contraindication. Of the participants 
with NT-proBNP >900ng/L that were referred to a cardiologist, two received a pace-
maker, one was planned for coronary angiography and three of the participants were 
planned for aortic valve replacement. Thus, eight participants (0.2%) underwent 
invasive downstream therapy due to participation in the screening.
6.2 STUDY II
In total, 6,868 participants were included in the STROKESTOP II study. Previously 
known AF was found in 553 (8.1%) of the participants and those were excluded 
from analysis leaving 6,315 participants. Out of these 19 (0.3%) participants had no 
pulse palpation performed and in 137 (2.2%) participants the single-lead ECG was 
considered to be of insufficient signal quality with no 12-lead ECG obtained. These 
were excluded, leaving 6,159 participants included in data analysis, see Figure 23.  
Figure 23. The study flow chart
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Baseline characteristics of participants with regular and irregular pulse are shown in 
Table 8. Female sex, congestive heart failure, hypertension and history of palpita-
tions were significantly more frequent in participants with irregular pulse.
6.2.1 AF screening accuracy of pulse palpation
Irregular pulse was found in 461 out of 6,159 (7.5%) participants. AF was diagnosed 
in 22 of those with irregular pulse (4.8%). The largest part of the participants had 
regular pulse (n=5,689) and of those, six were diagnosed with AF during the visit 
(0.1%). In total AF was diagnosed in a total of 28 participants at the single-time-
point visit, see Figure 24. 
Sensitivity of pulse palpation was 78.6 %, specificity 92.9 %, positive predictive 
value 4.8 % and negative predictive value 99.9 %, yielding a total diagnostic accu-
racy of pulse palpation of 92.8 %, the test performance is shown in Table 9.
Included participants Regular pulse (n=5698) Irregular pulse (n=461) p-value
Congestive heart failure n (%) 62 (1.1%) 11 (2.4%) 0.013
Hypertension n (%) 2,880 (50.5%) 259 (56.2%) 0.020
Diabetes mellitus n (%) 614 (10.8%) 48 (10.4%) 0.808
Stroke/TIA/thrombo-embolism n (%) 401 (7.1%) 39 (8.5%) 0.254
Vascular disease n (%) 349 (6.1%) 33 (7.2%) 0.376
Female n (%) 3,220 (56.5%) 215 (46.6%) <0.001
History of palpitations n (%) 1,664 (29.2%) 163 (35.4%) 0.005










Figure 24. Test performance of pulse palpation. 
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To diagnose one case of new AF after irregular pulse palpation, 21 ECGs had to be 
taken. No other significant brady- or tachycardia was identified on the single-lead 
ECGs. 
A sensitivity analysis was done in which 93 of the 137 participants with poor sig-
nal quality on the index single-lead ECG but missing a 12-lead ECG were included. 
Results from the two weeks screening following the screening visit were imputed 
and in case a new AF had been diagnosed during the two weeks A “worst-case sce-
nario” was defined as if the index-ECG had also shown AF. A “best-case scenario” 
was defined as if none of the individuals with new AF during two weeks of screening 
had had AF on the index-ECG. The test performance of pulse palpation for the two 
different scenarios are shown in Table 10.
Included participants Participants (n=6159)
Irregular pulse, AF on single-lead ECG (True positives) 22
Regular pulse, no AF on single-lead ECG (True negatives) 5,692
Irregular pulse, no AF on single-lead ECG (False positives) 439
Regular pulse, AF on single-lead ECG (False negatives) 6
Pre-test probability (prevalence) 0.5% (0.3%, 0.7%)
Sensitivity (95% CI) 78.6% (59.0%, 91.7%)
Specificity (95% CI) 92.8% (92.2%, 93.5%)
Positive predictive value (95% CI) 4.8% (3%, 7.1%)
Negative predictive value (95% CI) 99.9% (99.8%, 100%)
Positive likelihood ratio (95% CI) 11.0 (8.7, 13.6)
Negative likelihood ratio (95% CI) 0.23 (0.1, 0.5)
Post-test probability if positive likelihood ratio 5%
Post-test probability if negative likelihood ratio 0%





Irregular pulse, AF on single-lead ECG (True positives) 24 22
Regular pulse, no AF on single-lead ECG (True nega-
tives)
5772 5777
Irregular pulse, no AF on single-lead ECG (False posi-
tives)
445 447
Regular pulse, AF on single-lead ECG (False negatives) 11 6
Pre-test probability (prevalence) 0.6% (0.4%, 0.8%) 0.4% (0.3%, 0.6%)
Sensitivity (95% CI) 68.6% (50.7%, 83.1%) 78.6% (59%, 91.7%)
Specificity (95% CI) 92.8% (92.2%, 93.5%) 92.8% (92.1%, 93.4%)
Positive predictive value (95% CI) 5.1% (3.3%, 7.5%) 4.7% (3.0%, 7.0%)
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6.2.2 Symptoms
History of palpitations was found in 1,827/6,159 (29.7%) of the participants. New 
AF was diagnosed in 11 (0.6%) of the participants with history of palpitations. Most 
participants reported no history of palpitations, 4,332/6,159 (70.3%) and AF was 
diagnosed in 14 (0.3%) of them. There was no significant difference in the detection 
of new AF between symptomatic and asymptomatic participants, see test perfor-
mance stratified by symptoms in Table 11. In participants diagnosed with new AF, 
39% reported having had a history of palpitations. 
6.3 STUDY III
The overall participation rate in the STROKESTOP II study was 48.6%, a significant 
increase from the participation in STROKESTOP I in which the uptake was 46.9%in 
the Stockholm region (p=0.006). Shown in Figure 25 are statistical certainty geo-
maps of participation in the STROKESTOP I study and the STROKESTOP II study 
Negative predictive value (95% CI) 99.8% (99.7%, 99.9%) 99.9% (99.8%, 100%)
Positive likelihood ratio (95% CI) 9.6 (7.5, 12.2) 10.9 (8.8, 13.5)
Negative likelihood ratio (95% CI) 0.34 (0.2, 0.6) 0.2 (0.1, 0.5)
Post-test probability if positive likelihood ratio 5% 5% 
Post-test probability if negative likelihood ratio 0% 0%
Table 10. “Worst case scenario” and “Best case scenario” sensitivity analysis
Included participants History of palpita-
tions (n=1827)
No history of palpita-
tions (n=4332)
Irregular pulse, AF on single-lead ECG (True positives) 8 14
Regular pulse, no AF on single-lead ECG (True nega-
tives)
1661 4031
Irregular pulse, no AF on single-lead ECG (False posi-
tives)
155 284
Regular pulse, AF on single-lead ECG (False negatives) 3 3
Pre-test probability (prevalence) 0.6% (0.3%, 1.1%) 0.4% (0.2%, 0.6%)
Sensitivity (95% CI) 72.7% (39.0%, 94.0%) 82.4% (56.6%, 96.2%)
Specificity (95% CI) 91.5% (90.1%, 92.7%) 93.4% (92.6%, 94.1%)
Positive predictive value (95% CI) 4.9% (2.1%, 9.4%) 4.7% (2.6%, 7.8%)
Negative predictive value (95% CI) 99.8% (99.5%, 100%) 99.9% (99.8%, 100%)
Positive likelihood ratio (95% CI) 8.5 (5.8, 12.6) 12.5 (9.8, 16)
Negative likelihood ratio (95% CI) 0.3 (0.1, 0.8) 0.2 (0.1, 0.5)
Post-test probability if positive likelihood ratio 5% 5%
Post-test probability if negative likelihood ratio 0% 0%
Table 11. Test performance of pulse palpation stratified by symptoms compared to single-lead ECG
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in Stockholm county displaying, for each of the 99 residential parishes, spatially 
smoothed participation rates (PRs). 
The addition of the two new southern Stockholm sites in the STROKESTOP II study 
increased participation rates in those areas. In comparison the northern region fell 
out red in the STROKESTOP II study. This was due to increased uptake in the south-
ern part, not because of lower actual uptake rates between the STROKESTOP trials. 
When compared to the same catchment areas and corresponding rates from the 
STROKESTOP I study, the participation rates were significantly higher in the areas 
where an additional screening site had been added. In the area surrounding the Kar-
olinska University Hospital site the uptake increased from 41% to 47% (p<0.001), 
i.e. a 15% relative increase. In the vicinity of the Södertälje Hospital site, the uptake 
increased from 28% to 43% (p<0.001), i.e. a relative increase of 54%. The uptake was 
not significantly changed in the catchment area of the Sabbatsberg Hospital site (the 
one site used in both studies, but with a smaller catchment area in STROKESTOP 
II), going from 50% in STROKESTOP I to 49% in STROKESTOP II (p=0.17). In 
all three catchment areas, higher participation was observed among women, those 
with higher education, with higher income, among non-immigrants as well as among 
married individuals. These results are depicted in Table 12. 
 
Figure 25. Statistical geo-maps of participation in the STROKESTOP I (SS1) and STROKESTOP II 
(SS2) studies. 2020 Mar 30;969141320908316. doi: 10.1177/0969141320908316. Online ahead of 
print. Reprinted by permission of SAGE publications.
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The uptake was improved most markedly in the area around the Södertälje Hospital 
site, where a 1.5-fold increase was observed also in the socioeconomically weaker 


















SS1 1714 705 41 9517 4786 50 618 174 28
SS2 2086 983 47 <0.001 11240 5544 49 0.17 786 334 43 <0.001
By gender 
Male SS1 802 342 43 4311 2144 50 285 84 29
Male SS2 976 443 45 0.26 5306 2565 48 0.18 346 145 42 0.002
Female SS1 912 363 40 5260 2642 50 333 90 27
Female SS2 1110 540 49 <0.001 5934 2979 50 0.99 440 189 43 <0.001
By educational levelb
Primary school SS1 585 198 34 2573 1009 39 267 56 21
Primary school SS2 615 235 38 0.13 2475 912 37 0.09 262 85 32 0.004
Secondary school/higher SS1 1077 497 46 6759 3727 55 303 108 36
Secondary school/higher SS2 1414 739 52 0.003 8513 4584 54 0.11 470 243 52 <0.001
By disposable incomec
Low SS1 964 334 35 4258 1681 39 389 86 22
Low SS2 854 328 38 0.11 3354 1181 35 <0.001 369 119 32 0.002
Medium SS1 647 315 49 4066 2328 57 189 70 37
Medium SS2 989 509 51 0.29 5513 2900 53 <0.001 347 176 51 0.003
High SS1 100 54 54 1232 775 63 40 18 45
High SS2 243 146 60 0.36 2373 1463 62 0.48 70 39 56 0.38
By immigrant background 
Born in Sweden SS1 1199 527 44 7565 4021 53 432 136 31
Born in Sweden SS2 1551 795 51 <0.001 8952 4690 52 0.34 517 243 47 <0.001
Born outside of Sweden SS1 515 178 35 2006 765 38 186 38 20
Born outside of Sweden SS2 535 188 35 0.90 2288 854 37 0.61 269 91 34 0.003
By marital statusd
Married SS1  948 435 46 5077 2786 55 311 106 34
Married SS2 1194 617 52 0.009 5981 3209 54 0.21 427 200 47 <0.001
Divorced SS1  354 138 39 2011 906 45 131 32 24
Divorced SS2 420 175 42 0.49 2626 1172 45 0.80 169 73 43 0.001
Widow/widower SS1  311 107 34 1657 762 46 134 28 21
Widow/widower SS2 320 132 41 0.09 1499 684 46 0.87 134 46 34 0.02
Unmarried SS1  101 25 25 819 325 40 42 8 19
Unmarried SS2 152 59 39 0.03 1134 479 42 0.28 56 15 27 0.51
Table 12. Participation rates according to catchment area and socio-demographic characteristics in 
the STROKESTOP II (SS2) study, compared with corresponding rates in the STROKESTOP I (SS1) 
study. 2020 Mar 30;969141320908316. doi: 10.1177/0969141320908316. Online ahead of print. 
Reprinted by permission of SAGE Publications.
SS2, Strokestop 2 Study; SS1, Strokestop 1 Study 
a p-value based on the chi-squared test, comparing the participation rates between SS2 and SS1 for a given population 
group within the specified catchment area.
b Data on educational level were missing for 339 invited persons in SS1 and 363 invited persons in SS2. 
c Data on disposable income were missing for 18 invited persons in SS1. 
d Data on marital status were missing for 7 invited persons in SS1.
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population groups (from 21% to 32% participants in the low education group, from 
22% to 32% participants in the low-income group and from 31% to 47% participants 
in the immigrant group).
A univariate logistic regression analysis showed that the odds of participation in 
the STROKESTOP II study were highest among women, those with higher educa-
tion, with higher incomes, non-immigrants, married people and those living in the 
catchment area belonging to the Sabbatsberg Hospital site. The difference in odds 
ratio in all categories compared to reference was significant. In the multivariable 
analysis, the odds of attendance were consistent with those in the univariate analy-
sis, except in the catchment area where the difference became insignificant. These 
results are shown in Table 13.
Variable
Univariate analyses Multivariable analysis
Invited (n) Participants (n) % OR (95% CI) pa OR (95% CI) pa
Gender 0.02 <0.001
Men 6628 3153 47.6 1.00 (ref) 1.00 (ref))
Women 7484 3708 49.5 1.08 (1.01, 1.16) 1.43 (1.32, 1.54)
Educational level <0.001 <0.001
Primary school 3352 1232 36.8 1.00 (ref) 1.00 (ref)
Secondary school/higher 10397 5566 53.5 1.98 (1.83, 2.14) 1.65 (1.52, 1.79)
Unknown 363 63 17.4 0.36 (0.27, 0.48) 0.50 (0.37, 0.66)
Disposable income <0.001 <0.001
Low 4577 1628 35.6 1.00 (ref) 1.00 (ref)
Medium 6849 3585 52.3 1.99 (1.84, 2.15) 1.91 (1.75, 2.07)
High 2686 1648 61.4 2.88 (2.61, 3.17) 2.58 (2.31, 2.88)
Immigrant background <0.001 <0.001
Born outside Sweden 3092 1133 36.6 1.00 (ref) 1.00 (ref)
Born in Sweden 11020 5728 52.0 1.87 (1.72, 2.03) 1.36 (1.24, 1.48)
Marital status <0.001 <0.001
Unmarried 1342 553 41.2 1.00 (ref) 1.00 (ref)
Widow/widower 1953 862 44.1 1.13 (0.98, 1.30) 0.97 (0.84, 1.13)
Divorced 3215 1420 44.2 1.13 (0.99, 1.28) 1.06 (0.93, 1.21)
Married 7602 4026 53.0 1.61 (1.43, 1.81) 1.56 (1.38, 1.76)
Catchment area <0.001 0.59
Södertälje Hospital 786 334 42.5 1.00 (ref) 1.00 (ref)
Karolinska University 
Hospital
2086 983 47.1 1.21 (1.02, 1.42) 1.07 (0.90, 1.27)
Sabbatsberg Hospital 11240 5544 49.3 1.32 (1.14, 1.52) 1.02 (0.87, 1.19)
Table 13. Results from logistic regression analysis based on data from the STROKESTOP II study. 
2020 Mar 30;969141320908316. doi: 10.1177/0969141320908316. Online ahead of print. Reprinted 
by permission of SAGE Publications.
SS2, Strokestop 2 Study
a p-value for variable.
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6.4 STUDY IV
6.4.1 Non-participants and participants’ characteristics
Included in the analysis were 6868 participants and 7086 non-participants. Excluded 
were individuals who died (n = 340) or emigrated from Sweden (n = 10) prior to 
having received their last invitation. 
Non-participants were more likely to have been hospitalized in the last 5 years, 
spent more days being hospitalized over the last year prior to index date and were 
discharged to a retirement home more frequently when compared to participants. 
The proportion of multimorbid individuals was higher in the non-participants group 
and they had higher CHA2DS2-VASc scores as well as higher Charlson’s comorbid-
ity index than the participant group. Non-participants were more likely unmarried, 
only received primary education, had lower income and were immigrants to a higher 
degree than the participants. 
The prevalence of prior AF in non-participants was significantly higher than in 
the participants, 17.9% and 8.9% respectively (p<0.001). All medical diseases were 
more prevalent in non-participants than participants.
All types of prescribed medications included in our dataset were more common 
in non-participants than participants and non-participants had a higher number of 
unique Anatomical Therapeutic Chemical (ATC)-codes dispensed over the last 3 
years than participants. Characteristics of participants vs. non-participants are shown 






General and socioeconomic characteristics
Female (%) 3703 (52.3) 3710 (54.0) 0,039
Outpatient visits (total over last 5 years) 
(mean (SD)) 16.51 (26.39) 16.15(15.91) 0,330
Hospitalizations (total over last 5 years) 
(mean (SD)) 1.91 (3.44) 1.01 (1.99) <0.001
Days spent hospitalized last year prior to 
index (mean (SD)) 2.90 (10.48) 0.70 (3.67) <0.001
Charlson’s comorbidity index (weighted) 
(mean (SD)) 1.39 (1.90) 0.95 (1.55) <0.001
Multimorbidity (%) 1185 (16.7) 943 (13.7) <0.001
Discharged to retirement home (last 3 years) 
(%) 181 (2.6) 15 (0.2) <0.001
Marital status: Married (%) 3454 (48.7) 3977 (57.9) <0.001
Marital status: Unmarried (%) 759 (10.7) 552 (8.0) <0.001
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Marital status: Divorced (%) 1737 (24.5) 1416 (20.6) <0.001
Marital status: Widowed (%) 1136 (16.0) 923 (13.4) <0.001
Educational attainment: Tertiary (%) 1902 (26.8) 2799 (40.8) <0.001
Educational attainment: Secondary (%) 2809 (39.6) 2774 (40.4) 0,376
Educational attainment: Primary (%) 2079 (29.3) 1232 (17.9) <0.001
Educational attainment: Missing (%) 296 (4.2) 63 (0.9) <0.001
Disposable income: Low (%) 2681 (37.8) 1519 (22.1) <0.001
Disposable income: Medium (%) 3413 (48.2) 3823 (55.7) <0.001
Disposable income: High (%) 992 (14.0) 1526 (22.2) <0.001
Born in Sweden (%) 5162 (72.8) 5734 (83.5) <0.001
Medical history
Ischemic stroke (%) 547 (7.7) 242 (3.5) <0.001
Total atrial fibrillation prevalence (%) 1267 (17.9) 610 (8.9) <0.001
Medicated atrial fibrillation (on OAC treat-
ment) (%) 1178 (16.6) 551 (8.0) <0.001
CHA2DS2-VASc score (mean (SD)) 3.68 (1.33) 3.27 (1.07) <0.001
Pulmonary embolism (%) 162 (2.3) 109 (1.6) 0,003
Thromboembolism (%) 955 (13.5) 553 (8.1) <0.001
Intracerebral bleeding (%) 97 (1.4) 32 (0.5) <0.001
Other intracranial bleeding (%) 146 (2.1) 79 (1.2) <0.001
Hospitalization due to bleeding (%) 833 (11.8) 479 (7.0) <0.001
Anaemia (%) 738 (10.4) 365 (5.3) <0.001
Myocardial infarction (%) 743 (10.5) 376 (5.5) <0.001
Vascular disease (%) 743 (10.5) 376 (5.5) <0.001
Peripheral artery disease (%) 465 (6.6) 228 (3.3) <0.001
Heart failure (%) 771 (10.9) 269 (3.9) <0.001
Mitral stenosis (%) 14 (0.2) 8 (0.1) 0,32
Mechanical prosthetic valve (%) 50 (0.7) 23 (0.3) 0,004
Pacemaker (%) 288 (4.1) 133 (1.9) <0.001
Hypertension (%) 3373 (47.6) 2387 (34.8) <0.001
Hyperlipidemia (%) 1199 (16.9) 915 (13.3) <0.001
Diabetes (%) 1408 (19.9) 845 (12.3) <0.001
Liver disease (%) 156 (2.2) 90 (1.3) <0.001
Chronic kidney disease (%) 331 (4.7) 129 (1.9) <0.001
Hypothyroidism (%) 397 (5.6) 351 (5.1) 0,21
Thyrotoxicosis (%) 12 (0.2) 13 (0.2) 0,938
Chronic obstructive pulmonary disease (%) 641 (9.0) 278 (4.0) <0.001
Rheumatoid arthritis (%) 157 (2.2) 146 (2.1) 0,76
Osteoarthritis (%) 1602 (22.6) 1826 (26.6) <0.001
Alcohol index (%) 414 (5.8) 141 (2.1) <0.001
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6.4.2 Factors predicting participation
The twenty-five most important variables predicting participation are shown in Fig-
ure 26. Low disposable income was the variable with the strongest influence on 
participation. It had a very negative influence on participation. The frequency of hos-
pitalisations had a negative proportional influence on participation - the more hospi-
talisations, the lower the participation rate. Similarly, the higher the CHA2DS2-VASc 
score was the more negative influence it had on participation. Tertiary education was 
the fifth most important variable, but it was the first one with a positive influence on 
participation. Dementia was the disease with the strongest negative influence on the 
participation and the seventh most important variable.
Dementia (%) 461 (6.5) 70 (1.0) <0.001
Cancer (last 3 years) (%) 819 (11.6) 637 (9.3) <0.001
Parkinson's disease (%) 257 (3.6) 156 (2.3) <0.001
Psychiatric diseases (%) 531 (7.5) 254 (3.7) <0.001
Medicine dispensations
Anticoagulants (%) 3251 (45.9) 2162 (31.5) <0.001
Psychiatric medications (%) 1366 (19.3) 736 (10.7) <0.001
Neuroleptics (%) 279 (3.9) 54 (0.8) <0.001
Parkinson's disease medications (%) 227 (3.2) 118 (1.7) <0.001
COPD medication (%) 1186 (16.7) 943 (13.7) <0.001
Diabetes medications and insulin (%) 1164 (16.4) 672 (9.8) <0.001
Antihypertensives (%) 92 (1.3) 70 (1.0) 0,144
Diuretics (%) 1637 (23.1) 1058 (15.4) <0.001
Beta blockers (%) 2927 (41.3) 1934 (28.2) <0.001
Calcium antagonists (%) 2130 (30.1) 1582 (23.0) <0.001
RAAS inhibitors (%) 3597 (50.8) 3017 (43.9) <0.001
Lipid lowering agents (%) 2794 (39.4) 2296 (33.4) <0.001
Unique ATC-codes with repeated consump-
tion (last 3 years) (mean (SD)) 8.92 (6.97) 7.23 (5.69) <0.001
Table 14. Characteristics of non-participants versus participants.
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When all individuals in the intention-to-screen group were divided into quartiles 
according to the propensity score for participation, individuals in the quartile 1 (Q1) 
had the lowest propensity score for participation and individuals in quartile 4 (Q4) 
had the highest propensity score for participation. Individuals in Q1 had the lowest 
socioeconomic status, more medical conditions and had the highest amount of pre-
scription medicine dispensing whereas the opposite applied to the individuals in Q4. 
This is shown in Table 15.
Outpatient visits (t−4 years from index)
Educational attainment: Missing
Disposable income: High
Outpatient visits (t−1 year from index)
Outpatient visits (t−2 years from index)
Outpatient visits (t−3 years from index)
Psychiatric medications
Hypertension
Medicated atrial fibrillation (oral anticoagulantia)
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Figure 26. Variable importance for predicted participation


















Female (%) 1860 (53.3) 1758 (50.4) 1891 (54.2) 1904 (54.6) 0,002
Outpatient visits (total over 
last 5 years) (mean (SD)) 18.05 (33.22) 16.62 (20.48) 15.85 (15.53)
14.79 
(11.98) <0.001
Hospitalizations (total over 
last 5 years) (mean (SD)) 3.23 (4.63) 1.42 (2.03) 0.83 (1.36)  0.40 (0.72) <0.001
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Days spent hospitalized last 
year prior to index (mean 
(SD))
6.20 (14.85) 0.70 (2.60) 0.26 (1.08) 0.10 (0.51) <0.001
Charlson’s comorbidity index 
(weighted) (mean (SD)) 1.84 (2.07) 1.32 (1.74) 1.01 (1.64) 0.53 (1.16) <0.001
Multimorbidity (%) 843 (24.2) 505 (14.5) 401 (11.5) 379 (10.9) <0.001
Discharged to retirement 
home (last 3 years) (%) 173 (5.0) 21 (0.6) 1 (0.0) 1 (0.0) <0.001
Marital status: Married (%) 1518 (43.5) 1832 (52.5) 1945 (55.8) 2136 (61.2) <0.001
Marital status: Unmarried 
(%) 399 (11.4) 360 (10.3) 316 (9.1) 236 (6.8) <0.001
Marital status: Divorced (%) 952 (27.3) 821 (23.5) 713 (20.4) 667 (19.1) <0.001
Marital status: Widowed (%) 620 (17.8) 475 (13.6) 514 (14.7) 450 (12.9) <0.001
Educational attainment: 
Tertiary (%) 462 (13.2) 922 (26.4) 1310 (37.6) 2007 (57.5) <0.001
Educational attainment: 
Secondary (%) 1341 (38.4) 1518 (43.5) 1420 (40.7) 1304 (37.4) <0.001
Educational attainment: 
Primary (%) 1392 (39.9) 1014 (29.1) 736 (21.1) 169 (4.8) <0.001
Educational attainment: 
Missing (%) 294 (8.4) 34 (1.0) 22 (0.6) 9 (0.3) <0.001
Disposable income: Low (%) 2048 (58.7) 1341 (38.4) 708 (20.3) 103 (3.0) <0.001
Disposable income: Medium 
(%) 1249 (35.8) 1699 (48.7) 2018 (57.9) 2270 (65.1) <0.001
Disposable income: High (%) 192 (5.5) 448 (12.8) 762 (21.8) 1116 (32.0) <0.001
Born in Sweden (%) 2135 (61.2) 2593 (74.3) 2977 (85.3) 3191 (91.5) <0.001
Medical history
Ischemic stroke (%) 434 (12.4) 250 (7.2) 92 (2.6) 13 (0.4) <0.001
Atrial fibrillation (%) 960 (27.5) 742 (21.3) 163 (4.7) 12 (0.3) <0.001
Medicated atrial fibrillation 
(on OAC) (%) 917 (26.3) 697 (20.0) 115 (3.3) 0 (0.0) <0.001
CHA2DS2-VASc score (mean 
(SD)) 4.19 (1.50) 3.72 (1.17) 3.24 (0.91) 2.75 (0.65) <0.001
Pulmonary embolism (%) 112 (3.2) 68 (1.9) 60 (1.7) 31 (0.9) <0.001
Thromboembolism (%) 709 (20.3) 490 (14.0) 255 (7.3) 54 (1.5) <0.001
Intracerebral bleeding (%) 68 (1.9) 41 (1.2) 14 (0.4) 6 (0.2) <0.001
Other intracranial bleeding 
(%) 113 (3.2) 64 (1.8) 34 (1.0) 14 (0.4) <0.001
Hospitalisation due to bleed-
ing (%) 613 (17.6) 346 (9.9) 241 (6.9) 112 (3.2) <0.001
Anaemia (%) 584 (16.7) 266 (7.6) 164 (4.7) 89 (2.6) <0.001
Myocardial infarction (%) 609 (17.5) 372 (10.7) 123 (3.5) 15 (0.4) <0.001
Vascular disease (%) 609 (17.5) 372 (10.7) 123 (3.5) 15 (0.4) <0.001
Peripheral artery disease (%) 315 (9.0) 226 (6.5) 115 (3.3) 37 (1.1) <0.001
Heart failure (%) 739 (21.2) 261 (7.5) 37 (1.1) 3 (0.1) <0.001
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Mitral stenosis (%) 18 (0.5) 4 (0.1) 0 (0.0) 0 (0.0) <0.001
Mechanical prosthetic valve 
(%) 44 (1.3) 20 (0.6) 8 (0.2) 1 (0.0) <0.001
Pacemaker (%) 236 (6.8) 123 (3.5) 45 (1.3) 17 (0.5) <0.001
Hypertension (%) 2054 (58.9) 1911 (54.8) 1306 (37.4) 489 (14.0) <0.001
Hyperlipidemia (%) 787 (22.6) 702 (20.1) 461 (13.2) 164 (4.7) <0.001
Diabetes (%) 973 (27.9) 702 (20.1) 467 (13.4) 111 (3.2) <0.001
Liver disease (%) 92 (2.6) 78 (2.2) 50 (1.4) 26 (0.7) <0.001
Chronic kidney disease (%) 267 (7.7) 116 (3.3) 57 (1.6) 20 (0.6) <0.001
Hypothyroidism (%) 259 (7.4) 213 (6.1) 178 (5.1) 98 (2.8) <0.001
Thyrotoxicosis (%) 8 (0.2) 5 (0.1) 8 (0.2) 4 (0.1) 0,563
Chronic obstructive pulmo-
nary disease (%) 471 (13.5) 253 (7.3) 132 (3.8) 63 (1.8) <0.001
Rheumatoid arthritis (%) 80 (2.3) 90 (2.6) 76 (2.2) 57 (1.6) 0,052
Osteoarthritis (%) 803 (23.0) 877 (25.1) 865 (24.8) 883 (25.3) 0,098
Alcohol index (%) 257 (7.4) 155 (4.4) 122 (3.5) 21 (0.6) <0.001
Dementia (%) 501 (14.4) 30 (0.9) 0 (0.0) 0 (0.0) <0.001
Cancer (last 3 years) (%) 408 (11.7) 406 (11.6) 372 (10.7) 270 (7.7) <0.001
Parkinson's disease (%) 129 (3.7) 105 (3.0) 115 (3.3) 64 (1.8) <0.001
Psychiatric diseases (%) 359 (10.3) 204 (5.8) 152 (4.4) 70 (2.0) <0.001
Medicine dispensations
Anticoagulants (%) 2054 (58.9) 1907 (54.7) 1134 (32.5) 318 (9.1) <0.001
Psychiatric medications (%) 945 (27.1) 506 (14.5) 450 (12.9) 201 (5.8) <0.001
Neuroleptics (ATC: N05A) (%) 224 (6.4) 70 (2.0) 35 (1.0) 4 (0.1) <0.001
Parkinson's disease medica-
tions (%) 117 (3.4) 88 (2.5) 88 (2.5) 52 (1.5) <0.001
COPD medication (%) 718 (20.6) 549 (15.7) 486 (13.9) 376 (10.8) <0.001
Diabetes medications and 
insulin (%) 795 (22.8) 571 (16.4) 383 (11.0) 87 (2.5) <0.001
Antihypertensives (%) 58 (1.7) 54 (1.5) 29 (0.8) 21 (0.6) <0.001
Diuretics (%) 1144 (32.8) 769 (22.0) 522 (15.0) 260 (7.5) <0.001
Beta blockers (%) 1786 (51.2) 1771 (50.8) 1000 (28.7) 304 (8.7) <0.001
Calcium antagonists (%) 1127 (32.3) 1160 (33.3)  969 (27.8) 456 (13.1) <0.001
RAAS inhibitors (%) 1920 (55.0) 1962 (56.2) 1672 (47.9) 1060 (30.4) <0.001
Lipid lowering agents (%) 1660 (47.6) 1547 (44.4) 1211 (34.7) 672 (19.3) <0.001
Unique ATC-codes with 
repeated consumption (last 
3 years) (mean (SD))
10.97 (8.21) 8.90 (6.07) 7.38 (5.29) 5.10 (3.83) <0.001
Unique ATC-codes with 
repeated consumption (last 
3 years) (mean (SD))
10.97 (8.21) 8.90 (6.07) 7.38 (5.29) 5.10 (3.83) <0.001
Table 15. Characteristics of the intention-to-treat group stratified into quartiles by propensity score 
for participation
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When comparing inpatient and outpatient visits between the non-participants and 
participants over the last five year prior to index date, the non-participants had 
an increasing amount of hospitalizations over the years whereas the participants 
seemed to be on a plateau level. There was, however, no difference in outpatient 
visits between the groups, see Figure 27.
6.4.3 Potential yield of detection: Total AF prevalence and un-
treated AF prevalence
Observed prevalence of prior AF, unmedicated, new AF and untreated AF for partic-
ipants, and estimated prevalence among non-participants and in the entire population 
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Figure 27. Outpatient visits and hospitalizations in participants and non-participants over the last 
five years prior to index date
All participants Invited population 
(est via ATE weights
Non-participants 















Prior AF 12.41 (11.53, 13.34) 15.47 (14.36, 
16.65)
9,54 -5,93 0,62
Unmedicated prior AF 1.06 (0.83, 1.35) 1.14 (0.88, 1.49) 0,98 -0,17 0,85
New AF 2.34 (1.98, 2.77) 2.41 (1.97, 2.95) 2,27 -0,14 0,94
Untreated AF 3.4 (2.96, 3.9) 3.56 (3.03, 4.17) 3,25 -0,31 0,91
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CHA2DS2-VASc = 2 
(Women - 1) n = 3864
Invited population (est 
via ATE weights)
Non-participants 














Prior AF 4.76 (4.07, 5.56) 5.73 (4.87, 6.74) 4,01 -1,72 0,7
Unmedicated AF 1.01 (0.72, 1.42) 1.15 (0.81, 1.65) 0,91 -0,25 0,78
New AF 2.56 (2.04, 3.19) 2.79 (2.09, 3.7) 2,38 -0,4 0,85
Untreated AF 3.57 (2.97, 4.29) 3.94 (3.14, 4.93) 3,29 -0,65 0,83
CHA2DS2-VASc = 3 
(Women - 1) n = 1735
Invited population (est 
via ATE weights)
Non-participants 














Prior AF 14.75 (13.01, 16.67) 17.16 (15.12, 
19.41)
12,39 -4,77 0,72
Unmedicated AF 1.33 (0.87, 2.02) 1.39 (0.89, 2.16) 1,27 -0,12 0,91
New AF 2.42 (1.8, 3.25) 2.31 (1.69, 3.15) 2,54 0,23 1,1
Untreated AF 3.75 (2.94, 4.76) 3.69 (2.86, 4.75) 3,8 0,11 1,03
CHA2DS2-VASc = 4 
(Women - 1) n = 747
Invited population (est 
via ATE weights)
Non-participants 














Prior AF 22.94 (19.83, 26.38) 25.66 (22.18, 
29.48)
19,41 -6,25 0,76
Unmedicated AF 1.1 (0.51, 2.32) 1.22 (0.56, 2.65) 0,94 -0,28 0,77
New AF 2 (1.17, 3.42) 2.1 (1.18, 3.72) 1,87 -0,23 0,89
Untreated AF 3.1 (2, 4.77) 3.32 (2.09, 5.23) 2,81 -0,51 0,85
CHA2DS2-VASc >= 5 
(Women - 1) n = 522
Invited population (est 
via ATE weights)
Non-participants 














Prior AF 31.64 (27.5, 36.09) 34.66 (30.16, 
39.47)
26,82 -7,84 0,77
Unmedicated AF 0.54 (0.17, 1.73) 0.53 (0.15, 1.77) 0,57 0,05 1,09
New AF 1.47 (0.63, 3.37) 1.67 (0.69, 3.99) 1,15 -0,52 0,69
Untreated AF 2.01 (1.01, 3.97) 2.19 (1.05, 4.51) 1,72 -0,47 0,79
(est via ATU weights) Participants Difference 
(Participants - non-par-
ticipants)
Ratio (Participants / 
non-participants)
Table 16. Observed prevalence of prior AF, unmedicated prior AF, new AF and untreated AF sorted 
by CHA2DS2-VASc score for participants, and estimated prevalence among non-participants and in 
the entire intention-to-screen population
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The weighted estimates imply that the non-participants had 38% higher prevalence 
of known AF. The weighted estimates also imply that if the non-participants had 
participated the proportion of new AF would have been 2.4% in this group compared 
to 2.3% in the participants. The proportion of untreated AF among non-participants 
was estimated to 3.6% compared to 3.3% in the participants. 
When stratifying the intention-to-screen group into CHA2DS2-VASc scores 2, 3, 4, 
and >5 (- 1 point for females) the proportion of non-participants with prior AF grew 
with rising CHA2DS2-VASc score from 5.7% in the group with CHA2DS2-VASc 
score 2 to 34.7% in the group with CHA2DS2-VASc scores >5. The same applied 
to the participants, although the proportions were lower. The largest difference in 
untreated AF between participants and non-participants was found in the group with 
CHA2DS2-VASc score 2.
The outcome of untreated AF versus the propensity score of participation is shown 
in Figure 28. There was a trend towards a higher proportion of untreated AF in the 
lower propensity score levels for participation, but large confidence intervals make 
it difficult to make any inference on the relationship. 
Figure 28. Outcome of untreated AF vs. the propensity score of participation 
57
Screening for silent cardiac disease in an elderly population aiming at stroke reduction
7 DISCUSSION
7.1 MAJOR FINDINGS
In the first study, we found new AF in 4.4% of the participants in the high-risk group 
(NT-proBNP ≥125 ng/L), increasing the total prevalence of AF in all participants 
from 8.1% to 10.5%. Furthermore, 41% of the participants had low NT-proBNP 
levels (<125ng/L) and were only screened with one index single-lead ECG at the 
visit. In multivariable analysis of the high-risk group, NT-proBNP was the strongest 
predictor for new AF. 
In the second study, we found that pulse palpation had a low positive predictive 
value. For every irregular pulse palpated, 20 ECGs had to be taken to confirm one 
case of AF. The sensitivity of pulse palpation was modest. Almost one-third of the 
participants reported having a history of palpitations, but this did not predict new AF 
detection.
In the third study, we found that geographic distance to screening sites is of impor-
tance and by increasing the number of screening sites, screening participation can be 
significantly increased, even in groups of lower socioeconomic status. Socio-demo-
graphic factors have a significant impact on the screening participation.
In the fourth study, we found the hypothetical yield of new AF and untreated AF 
if the non-participants had attended screening was higher compared to the partici-
pants group. More individuals with high CHA2DS2-VASc scores were estimated to 
be in the non-participant group, underlining the fact that the non-participants would 
probably benefit from screening in case of new AF diagnosis, as they would be can-
didates for OAC treatment. We found that the non-participants could generally be 
considered poorer in health, of lower socioeconomic status and less mobile than the 
participants.
7.2 SCREENING FOR ATRIAL FIBRILLATION
Screening for AF seems to fit most of Wilson and Junger’s criteria for screening 
which are still considered the “gold standard” when considering screening for a 
particular disease. No less important is the statement, “The central idea of early 
disease detection and treatment is essentially simple. However, the path to its suc-
cessful achievement (on the one hand, bringing to treatment those with previously 
undetected disease and, on the other, avoiding harm to those persons not in need 
of treatment) is far from simple though sometimes it may appear deceptively easy.” 
(Principles and practice of screening for disease, 1968) (15)
A great deal of research is needed to determine which criteria should be used and 
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what processes are required to ensure that new screening programmes best serve 
the public interest. There is a growing amount of interest in screening for AF as it 
seems to check the right boxes for screening criteria, but there are knowledge gaps 
that have to be filled before taking action against this growing global epidemic. The 
most important gap to be filled is the lack of evidence that screening-detected AF and 
initiation of OAC treatment when indicated, reduces incidence or severity of stroke. 
In recent years many studies have been published on the topic of AF screening: 
the differences and advantages of opportunistic vs. systematic screening, different 
AF detection modalities and AF detection in different population groups, to name a 
few. In 2017 a white paper from the AF SCREEN international collaboration made a 
case for AF screening while recognising that randomised controlled trials with hard 
endpoints are still awaited (123). 
7.2.1 Systematic vs. opportunistic screening
Opportunistic screening is recommended (class I level B recommendation) in inter-
national guidelines and can be undertaken at relatively low cost by pulse taking, 
12-lead ECG or ECG rhythm strips for 30 seconds (8). Opportunistic screening has 
been considered to carry lower cost than systematic screening (21). The AF yield of 
single-time-point screening in >65-year-olds was 1,4% in a systematic review (124). 
Regardless of screening setting and considering that the majority of those identified 
had sufficiently high stroke risk to benefit from thromboprophylaxis, that has the 
potential to reduce stroke burden in societies. Both opportunistic and systematic 
screening were more cost-effective than routine practice in >65-year-olds (125).
Systematic screening should be considered (class II level A recommendation) in 
individuals >75-years of age or in those at high risk of stroke according to the 2020 
ESC AF Guidelines (8). Whether systematic screening is superior to opportunistic 
screening is an unanswered question, but randomised clinical trials are underway 
such as the STROKESTOP trials amongst others (10, 126). Because AF prevalence 
is on the rise and AF complications are predicted to increase over the next decades, 
such studies are important. While stroke is usually the primary end point being stud-
ied, an effect on all-cause mortality could be expected and also potentially on heart 
failure, myocardial infarction, and dementia could be expected. Hopefully, the ongo-
ing and planned studies will provide these answers.
A meta-analysis by Petryszyn et al. assessed the effectiveness of AF screening and 
its determinants and found that active screening for AF, whether it be systematic or 
opportunistic, was effective from 40 years of age. The organisation of the screening 
process seemed to be more important than the screening modalities. In a subgroup 
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analysis systematic screening was superior to opportunistic screening in identifying 
previously unknown AF (78). 
7.2.2 Whom to screen
The prevalence of AF increases with age (25). That fact makes screening for AF 
less cost-efficient in a population where the prevalence is too low. Also, the treat-
ment of the disease-in this case OAC treatment for stroke prevention-should be an 
option for those with newly discovered AF, and this is not always the case in younger 
individuals. In the Apple Heart Study 0,52% of the participants had irregular pulse 
and were offered to wear an ECG patch, of which 21% consented to. The AF yield 
in the age group >65 years was 35%, whereas in the age group <40 years it was 
18%. In total 0.04% were found to have AF of all participants (127). In study IV we 
found that the non-participants were not as mobile or as healthy as the participants in 
the STROKESTOP II study and untreated AF was higher in that group, underlining 
that this would be a group that would probably benefit from AF screening. For pol-
icy makers it is important that a screening program has clear health benefits and is 
cost-effective. A simulation model designed to find the optimal screening program in 
Swedish settings found that the most optimal program for AF screening, when all the 
possible designs of screening programs were considered, was screening at the age of 
75 years with the lowest cost per gained QALY (71). In both of the STROEKSTOP 
studies, 75/76-year-olds are invited for screening due to the fact that they are candi-
dates for OAC treatment by age alone (10, 126). Screening at the high age of 75 can 
offer specific logistic problems since some individuals are bound to be frail or multi-
morbid. There are few systematic screening programs conducted in this specific age 
group, although the Danish LOOP study included individuals >70 years of age with 
one or more risk factor for stroke (73) and the SAFER trial invited individuals >70 
years of age to participate (74). A Norwegian AF screening and prevalence study 
achieved a very high uptake in a 75-year old population using home visits, resulting 
in a higher uptake (82%) in this age-group (105). Current medical screening pro-
grams in Sweden are targeting lower age groups and these programs are reporting 
considerable higher uptake than the one reported from the STROKESTOP trials, 
implying that age and frailty are factors contributing to participation (128).
7.2.3 Benefits and harms of screening
Screenings amongst the elderly is a way of searching within a population that has a 
higher prevalence of AF and more often these individuals have a higher CHA2DS2-
VASc score, implicating they would probably benefit from OAC treatment. Inci-
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dentally found AF also seems to respond in the same way as clinically detected, 
so it seems logical that screening-detected AF would behave much the same (11). 
The most obvious benefit of screening to find AF in high-risk individuals would be 
the possible prevention of stroke. Other factors that could come from detecting AF 
through screening could be the possibility of preventing or early reversal of atrial 
remodelling, tachycardia induced cardiomyopathy, other AF related morbidity such 
as dementia, hospitalisations and mortality.
There are several potential harms that could come from AF screening. No screen-
ing tests report 100% sensitivity and specificity so there is always risk for false 
positives and false negatives. False positive tests could possibly cause overdiagnosis 
and overtreatment. A false negative test, on the other hand, could give false security 
as well as an untreated disease. There might be negative consequences and anxiety 
caused by being diagnosed with a disease; although, appropriate patient information 
and screening program organisation may reduce that anxiety. The UK SAFE study 
found higher levels of anxiety among participants that were diagnosed with AF, 
although the screening was tolerated by most (67). The risk of bleeding from OAC 
treatment is an important harm, a potentially life threatening one and that should be 
considered before initiating OAC treatment in any circumstances. The cost for the 
healthcare system by choosing to allocate resources to implement this intervention 
could be greater than the cost gained. These are all important points to consider 
either before or when screening may become a planned program. The United States 
Preventive Service Task Force (USPSTF) recommended against screening for AF 
and mainly based on lack of randomised controlled trials on stroke reduction as well 
as the concern that downstream treatment as a consequence of the screening could 
lead to complications otherwise not encountered (76). The Swedish authorities have 
also recommended against screening for AF using similar reasoning (129).
7.3 OAC INITIATION AND ADHERENCE 
Almost 95% of the participants in Study I accepted initiation of OAC, and of those 
96% were still adherent to the treatment at one-year follow-up. This is in accor-
dance with our previous results from AF screening trials (10). The high acceptance 
is likely at least partly be due to a predefined care pathway within the trial, which is 
something the 2020 ESC AF guidelines recommend (8). A dedicated research team 
taking responsibility for the entire screening process could, of course, affect the 
participants’ willingness to accept OAC therapy. Referring the patient outside the 
screening context, however, has been associated with lower OAC initiation rates 
(130). Participants with previously known AF had OAC treatment to a higher extent 
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in Study I than in STROKESTOP I (10). In study I the patients with new AF who 
were initiated on OAC treatment were to a very large extent (96%) adherent to the 
treatment after one year. These number are somewhat higher than those from another 
study from Stockholm, in which analysis of OAC treatment in AF patients between 
2011 and 2014 found 88.2% of AF patients adherent to OAC treatment after one 
year (131). Both the OAC acceptance and adherence in our studies is in line with 
considerable increase in OAC use in Sweden during the last five years (132).
7.4 NT-PROBNP IN ATRIAL FIBRILLATION SCREENING
Several previous studies have shown NT-proBNP to be a powerful predictor of inci-
dent AF as well as being a predictor for increased risk of stroke and death (133-136). 
This combination makes it a candidate for a biomarker to aid the decision on how 
to find those individuals at the highest risk and whom to screen for AF. Data from 
58,173 individuals in Europe with almost eight years median follow-up time found 
that patients with NT-proBNP over 82.2ng/L had twice the risk of both ischaemic 
and haemorrhagic stroke compared to those with NT-proBNP <20.4ng/L, confirming 
that NT-proBNP can be valuable in identifying those at higher risk for stroke (137). 
The cut-off of 125ng/L used in the STROKESTOP II study was derived from a 
sub-study to the STROKESTOP I study. After analysing NT-proBNP levels in about 
900 participants, it was found that using NT-proBNP of 125ng/L as cut-off would 
mean that 35% fewer participants would have had to undergo prolonged screening. 
This would reduce the cost of ECG equipment and interpretation as a result and miss 
at most a quarter of new AF cases (108). Based on these results, the hypothesis for 
the STROKESTOP II study was that stepwise screening with NT-proBNP would 
identify high-risk individuals for both AF, stroke and death. 
Although the low-risk group in study I was not investigated with repeated ECG 
recordings and some new AF cases probably went undetected in that group, the pro-
portion of participants diagnosed with AF on index ECG was markedly higher in the 
high-risk group, possibly confirming the discriminative performance of NT-proBNP.
NT-proBNP has repeatedly been shown to be one of the strongest predictors for AF 
development (100). When adding NT-proBNP to the multivariable analyses, heart 
failure became an insignificant factor for AF prediction in study I. This finding is 
similar to the findings of Hijazi et al. that clinical factors such as heart failure, dia-
betes, hypertension, other cardiovascular diseases and gender no longer added prog-
nostic value after adding biomarkers to the ABC-stroke risk score (46). Our results 
confirm those findings and call attention to the important addition of biomarkers 
such as NT-proBNP for improved AF screening.
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In a sub-study to the STROKESTOP II study, characteristics of participants with 
high NT-proBNP (>900ng/L) but no prior heart failure were described (138). Of 
93 participants, 30% had new AF and an additional 14% were found to have other 
clinically relevant cardiovascular comorbidities, indicating that higher levels of 
NT-proBNP justify further clinical investigation.
7.5 DIAGNOSTIC PERFORMANCE OF SCREENING MO-
DALITIES
The ESC AF Guidelines have since 2012 recommend pulse palpation or a rhythm 
strip in opportunistic screening for AF (8). Pulse palpation is a readily available, 
low-cost triage test that needs verification with ECG in case of irregular pulse. In 
Study II, we found a lower sensitivity (78.6%) than Hobbs et al. found in the SAFE 
study (87.2%) (67). Lower sensitivity means a higher false negative rate, which is 
regarded as an undesirable effect in a triage test because it means we would miss 
out on a disease that is present. The negative effects of failure to recognise AF, and 
thereby increasing the patient’s risk for stroke cannot be stressed enough. A study 
performed in a real-life setting in general practice in Denmark where a 12-lead ECG 
was performed in case of irregular pulse showed a similarly low positive predictive 
value for the pulse palpation test (5.1 %) in the age group 75-84 years (139). When 
asking patients to palpate their own pulse and register as regular or irregular before 
recording a single-lead ECG in a multicentre primary care study in Sweden, sensitiv-
ity was only 25 % per measurement occasion (20). Tests of irregular pulse are triage 
tests, whereas single-lead ECG devices have shown good diagnostic accuracy (10, 
140). Recording a single-lead ECG takes about the same amount of time to perform 
as pulse palpation, but the diagnosis can be confirmed instantly in most cases. 
Improved AF detection in high-risk individuals has the potential of reducing 
AF-related stroke and in recent years new rhythm-monitoring technologies have 
been evolving quickly. A review from 2018 examined the evidence supporting the 
use of some of the newer technologies (79) and in an era of rapid technological 
advances and the many emerging new instruments for detecting irregular pulse as 
well as easy to use single-lead ECG recordings, there might be room for more pre-
cise methods than pulse palpation. The medical society and research cannot always 
keep up with new technology; nonetheless, focus needs to be on evidence-based 
medicine, and accuracy studies are important. It is up to the medical community to 
sort out the different options and make educated recommendations to patients and 
health care systems. In the recent 2020 ESC AF Guidelines patient participation and 
patient-centered health care is stressed. Additionally, mobile technology with the 
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possibility of providing practices with easy-to-use rhythm devices and the public 
with self-screening devices is most likely going to be a part of that goal (8). 
7.6 SYMPTOMS OF PALPITATIONS IN ATRIAL FIBRILLA-
TION SCREENING
Palpitations are the most common symptom in AF patients (64, 141). The propor-
tion of individuals in Study II that had new AF and reported history of palpitations 
was 39 %, similar to what Siontis et al. found (40%) in their study on patients with 
previously known AF (64). Asymptomatic AF patients appear to have a higher risk 
of stroke and one-year mortality than symptomatic patients (142). Asymptomatic 
patients should be treated based on the same principles as symptomatic patients, and 
efforts should be put into treating concomitant conditions. OAC treatment should 
also be initiated if indicated (143). 
In clinical practice, patients reporting symptoms of palpitations could be assessed 
by pulse palpation as a triage test, but our results from Study II show that the post-
test probabilities of pulse palpation do not change with symptoms. Hence, history of 
palpitations did not predict new AF detection. 
7.7 SCREENING PARTICIPATION AND SCREENING PAR-
TICIPANTS
For any screening to be successful, individuals have to participate, regardless of 
their socioeconomic status, health status or other specific characteristics. Studies III 
and IV focus on both socioeconomic and medical characteristics of the participants 
compared to non-participants in the STROKESTOP II study. 
In Study III we illustrated that geographic distance to the screening site was of high 
importance and that increasing the number of sites has the potential to significantly 
increase uptake in screening studies. In the Danish VIVA study, a population study 
on screening for vascular disease, specially trained nurses operated mobile clinics in 
hospitals, general practitioners’ offices or even in a town hall, resulting in an uptake 
of 74.7% among men aged 65-74 years (104). We also found that sociodemographic 
factors had a significant impact on AF-screening-program participation. As in the 
STROKESTOP I study, the individuals with the highest odds of attending were those 
with higher education, high income, those who were married and non-immigrants 
(103). In Study IV we found that the factor with the strongest negative influence 
on participation was low income. This confirms results from a previous study by 
Zarrouk et al. in which 65-year-old men were invited to an abdominal aortic aneu-
rysm screening program and those with lower socioeconomic status showed lower 
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participation (144). By adding new screening sites in the STROKESTOP II study in 
deprived areas, we observed a markedly increased participation in population groups 
with low socioeconomic status. These results reinforce the importance of geographic 
proximity in screening, especially for those of lower socioeconomic status. A recent 
systematic review found that individuals with lower socioeconomic status showed 
poorer outcomes when AF was present (23), which is an important reason to attempt 
to lower the socioeconomic gradient in AF screening. A systematic review found that 
barriers and facilitators to participation in health checks for cardiometabolic disease 
were heterogenous, which makes it difficult to develop a “one size fits all” approach 
for increased uptake (145).
In study IV a detailed description of non-participants found that they were gener-
ally in poorer health, had lower socioeconomic status and were not as mobile. They 
had spent more days in hospital both during the last year as well as during the last 
five years, a sign of more morbidities and frailty. The CHA2DS2-VASc score was 
higher among non-participants, highlighting that these are the individuals at high 
risk for stroke if diagnosed with new AF. The gradient of the CHA2DS2-VASc score 
ranging from significantly higher in the Q1 to lower in Q4 could be interpreted as a 
proxy that the screening benefit would be largest in the group least likely to attend.
In the non-participants group a larger proportion of previously known AF was 
found than in the participants group. Possibly indicating that individuals with a prior 
diagnosis of AF would not see the point in attending an AF screening study. On the 
other hand, it could also be result of these individuals having been in contact with the 
healthcare system because of other morbidities and thereby having been diagnosed 
with AF. The difference in untreated AF between participants and non-participants, 
where non-participants had a higher proportion of untreated AF, was largest in the 
group with CHA2DS2-VASc scores 2, which could possibly be a sign of those indi-
viduals being healthier and not having had contact with the healthcare system result-
ing in subclinical AF no being identified. 
Interestingly, the overlapping of characteristics in both participants and non-par-
ticipants unveils that no single factor is the reason of non-attendance. Although the 
difference between the groups was significant in most categories, there were still 
individuals that attended the screening with dementia, Parkinson’s disease, alcohol 
problems to name a few, which we would have expected would possibly deter par-
ticipation altogether.
The number of non-participants that had been hospitalised gives way to further 
explorations of systematic AF screening within the in-hospital setting to identify 
high-risk and frail patients with new AF. A Belgian study where older adults were 
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screened for AF in a geriatric ward in a hospital setting demonstrated the feasibility 
of this approach and identified a significant number of patients with new AF (140). 
We found no difference in number of outpatient visits in the two groups, possibly 
highlighting that inpatient care is a strong sign of frailty and morbidity whereas 
outpatient visits could be a way of primary prevention.
7.8 LIMITATIONS
Systematic screening is a costly public health intervention thus there needs to be 
enough scientific evidence that it is of greater good for public health and society. 
Luckily, several large-scale, randomised, controlled systematic screening studies are 
ongoing that aim to answer the question if screening indeed does reduce stroke and/
or death, the STROKESTOP trials being among them.
In this thesis the study population was 75/76-year-olds in the Stockholm region. 
That fact is important when considering the external validity of the studies and how 
the results can be applied to other populations. However, this age group has been 
found to be optimal in simulation studies for AF screening (71) and the setting of the 
screening, with invitation by mail and lack of exclusion criteria could possibly be the 
scenario of a future real-life screening program. The participants in STROKESTOP 
II were found to be healthier than the non-participants which has to be considered 
when applying these results to other populations.
In study I the participation was slightly lower than expected, and the participants 
had moderate mean CHA2DS2-VASc score, suggesting that the ones attending the 
screening might have been healthier than the non-participants. That indication was 
confirmed in Study IV. Medical history in study I was self-reported without confir-
mation from medical records, which could have affected validity of medical history 
data. As for the predictors for AF in our multivariable analysis, we were restricted to 
the variables collected within the trial so there is always risk for unknown residual 
confounding. As for the AF diagnosis in this study, the low-risk group only per-
formed one single-lead ECG at the screening visit, so AF could be underdiagnosed 
in this group.  The hypothesis, however, is that individuals in the group with low 
NT-proBNP have a lower risk for both incident AF as well as stroke, something that 
will be evaluated in our final analysis of the STROKESTOP II study in a five years’ 
time.
Study II is a diagnostic accuracy study on pulse palpation compared to single-lead 
ECG. The gold standard of rhythm interpretation is considered to be a 12-lead ECG, 
but we did not perform 12-lead ECGs on all participants in this study. The 2020 ESC 
AF Guidelines recommend 30-second rhythm strip for diagnosing AF, and a 12-lead 
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ECG is not needed to confirm that diagnosis. The aim of this study was to diagnose 
AF rhythm and no other specific arrhythmia. Single-lead ECGs can be difficult to 
interpret if the signal quality, which necessitates a 12-lead ECG, is poor. 
Participants were not asked to specify their palpitation symptoms any further than 
to answer a simple yes/no question making it only possible to infer on history of 
palpitations.
Pulse palpation was performed by trained healthcare professionals after instruc-
tions, which could have increased the accuracy of pulse palpation. There might be 
observer variability as the subjective element cannot be excluded from pulse pal-
pation. Although care was taken to ensure that pulse palpitation was performed 
without results of the single-lead ECG, there is a possibility of reviewer bias after 
the single-lead ECG or clinical review bias as the patients reported their medical 
history. We did not evaluate the intra- or interobserver variability of the cardiologists 
studying the 12-lead ECGs in the study. 
The intrinsic factors of a diagnostic test (sensitivity and specificity) do not depend 
on disease prevalence, but the predictive values are strongly dependent on disease 
prevalence. AF prevalence in this cohort was 0.5%, and the negative predictive value 
becomes very high due to that fact. This this has to be taken into account when 
applying these results to other populations.
In Study III data on participants from the STROKESTOP I and STROKESTOP 
II studies were collected a few years apart, and the demographics of the areas 
compared may have changed in between the data withdrawal. This may have pos-
sibly introduced misclassification bias. In the STROKESTOP II study there was 
a lower proportion of individuals in the lowest income category compared to the 
STROKESTOP I study. This may have introduced a bias where we would detect a 
difference because of demographics rather than participation rate. 
The changes (website, more languages in the patient information, more sites) made 
to increase the screening uptake cannot be separated, hence which had the strongest 
impact is a question this study cannot answer. This feature may decrease the external 
validity of this study.
In Study IV 75/76-year-olds in the Stockholm region were studied. This has to 
be considered when applying the results to other groups or other settings. While 
the analyses included rich information on medical history, pharmaceutical dispen-
sations and socioeconomic status, there may be other factors that predict screening 
participation that we were unable to measure. In addition, while the registers we 
relied on are considered to be of high quality (146, 147) we cannot rule out mea-
surement errors such as missing or misclassified diagnoses. The healthcare registers 
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in Sweden collect prospectively data covering the entire public hospital-associated 
health care system in Sweden. This is beneficial for external validity, particularly 
for countries with similar patient compositions and health care systems, but as we 
did not have information on private health care and primary health, the data set may 
have some gaps. 
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8 CONCLUSIONS
Using NT-proBNP in a stepwise, systematic AF screening study yielded a large pro-
portion of new AF cases (4.4%) in the group with elevated NT-proBNP, increasing 
the prevalence in participants by almost one third. NT-proBNP was the strongest 
predictor of new AF. OAC treatment was well accepted in the group diagnosed with 
new AF and compliance to the treatment at one-year follow-up was high.
Pulse palpation was inferior to single-lead ECG when screening for AF. We would 
advocate using a single-lead ECG, from which the diagnosis of AF can be made 
simultaneously rather than the triage test of pulse palpation. History of palpitations 
did not predict new AF during this single-time point screening.
Decentralisation of screening sites had a positive impact on screening participa-
tion. The positive effect was found not only in the groups already with higher odds of 
attending, but also in the groups of lower socioeconomic status who have lower odds 
of attending. This indicates that bringing the screening closer to neighbourhoods 
with lower socioeconomic status lowers the socioeconomic gradient often seen in 
screening. 
The potential yield of untreated atrial fibrillation was higher among non-partici-
pants in the STROKESTOP II study than among those that participated. Non-partic-
ipants were of poorer health, had lower socioeconomic status and were less mobile 
than participants. They also had higher CHA2DS2-VASc scores, highlighting their 
high stroke-risk and probable gain from attending screening.
69
Screening for silent cardiac disease in an elderly population aiming at stroke reduction
9 CLINICAL IMPLICATIONS
Whether or not NT-proBNP can be used as an aid to decide whom to screen for AF 
and whether it is cost-effective for society, are questions we as of yet do not have 
the answers to but hope to have in a few years’ time. What we did find in study I 
was that NT-proBNP was the strongest factor predicting new AF in a multivariable 
analysis and a 50% higher proportion of individuals were diagnosed with AF in 
the high-risk group in STROKESTOP II than were found in the whole group in the 
STROKESTOP I study. In a sub-study to the STROKESTOP II study in participants 
with NT-proBNP >900ng/L, 30% of the patients were diagnosed with new AF. Our 
results support the use of NT-proBNP and highlight its probably discriminative value 
in AF screening. In patients with NT-proBNP >125ng/L and even more so in those 
with NT-proBNP>900ng/L one should consider screening for AF. 
Pulse palpation is recommended according to the ESC AF Guidelines, but our 
results strengthen the case for more sensitive diagnostic tools for screening than 
pulse palpation. With today’s technological advances there are abundant, easy-to-use 
modalities that can diagnose AF directly and save clinicians and individuals from 
many false positive results of the pulse palpation test. 
Adding screening sites or in some way bringing the screening closer to more 
socioeconomically deprived areas would increase participation in these areas and, 
in that way, hopefully decrease the socioeconomic gradient that is found in many 
screening programs. 
Studying both socioeconomic- and health factors in non-participants we found 
that low income and hospitalisations had the strongest negative influence on par-
ticipation. In planning future screening scenarios focus should be put on how to 
reach those less likely to attend as they would benefit from the screening efforts e.g. 
by bringing the screening closer to low-income areas as well as possibly designing 
active screening in hospital environments.
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10 FUTURE PERSPECTIVE
Screening is a complex battery and so is AF so how to design an ideal screening 
program is obviously a very difficult question, possibly without one right answer. 
How societies around the world should design a screening program can vary because 
of different healthcare systems and priorities. 
In study I, NT-proBNP was used to try to identify high-risk individuals for incident 
AF. We found 50% more new AF cases in the high-risk group in the STROKESTOP 
II trial compared to the STROKESTOP I trial, in which all individuals underwent 
prolonged screening. This was in accordance with the expected yield of new AF in 
the high-risk group. NT-proBNP is associated with incident AF and finding the right 
biomarker, possibly one for finding AF and another one to predict which individuals 
have higher risk of suffering complications from OAC treatment is something that 
could be studied to better control and personalise treatment. 
Technological advances have been accelerating over the last decade and new 
modalities for detecting AF will probably be seeing the light of day in the next years. 
Which modality is optimal to screen for AF is sure to be the research object of many 
studies to come. 
By increasing the screening sites, individuals already more likely to attend screen-
ing reacted with increased participation. For the screening not to be a way of increas-
ing inequality even more we need to focus on reaching those in more socioeco-
nomically deprived areas and those that would benefit from screening. This could 
possibly be done by placing screening sites in socioeconomically deprived areas, 
possibly using general practices, hospitals or by using mobile screening clinics.
In study IV we found that participation was worse in low-income, high-risk and 
hospitalised individuals. The results from study IV could potentially help when 
designing future screening programs or future screening studies. Focus should be 
put on how to include those with lower income and studies could try to find what 
factors can have a positive effect on individuals in low-income groups. It would 
also be interesting to study systematic screening in hospitalised patients, as a way of 
reaching those with many risk factors and at the same time include those that have 
more difficulty attending screening. 
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11 SVENSK SAMMANFATTNING
11.1 BAKGRUND
Kardiovaskulära sjukdomar är den vanligaste dödsorsaken i världen från 15 års ålder 
och uppåt. Där spelar förmaksflimmer en stor roll som den vanligaste kliniska hjärt-
arytmin som påverkar över 33 miljoner människor i världen. Förmaksflimmer är en 
ledande orsak till sjuklighet och död, där hjärtsvikt, stroke och död är de mest befa-
rade komplikationerna. Förmaksflimmer är en betydelsefull orsak till stroke men 
den risken kan minskas med åtminstone två-tredjedelar hos högriskpatienter genom 
att starta blodförtunnande behandling. Förmaksflimmer behöver inte ge symptom 
och-särskilt äldre individer-kan vara drabbade av förmaksflimmer utan att veta om 
det eller känna av det. Eftersom förmaksflimmer är ett vanligt och för de allra flesta 
ett kroniskt problem, spås bli ännu mer utbrett inom närmaste 50 åren och det finns 
en effektiv behandling verkar det uppfylla World Health Organisations kriterier för 
populationsscreening. Att screena för förmaksflimmer och sätta in blodförtunnande 
behandling när det är indicerat skulle kunna förhindra stroke och lidande för många. 
Om screening för förmaksflimmer minskar risken för stroke och samtidigt är kost-
nadseffektivt ur ett samhälleligt perspektiv är ännu en fråga utan svar. Tills dess 
pågår forskning för att försöka hitta den optimala screeningmetoden, vilket är bak-
grunden till STROKESTOP I och STROKESTOP II studierna.
11.2 SYFTE
Första delstudien syftar till att studera antal deltagare i STROKESTOP II studien 
som fick förmaksflimmerdiagnos efter att de sorterades i högrisk eller lågriskgrupper 
beroende på NT-proBNP värde. Vi studerade även hur stor andel av de som diagnos-
ticerades med förmaksflimmer blev insatta på blodförtunnande behandling och i hur 
stor utsträckning de fortfarande stod på behandlingen efter 1 år. 
I andra delstudien jämförde vi metoderna pulspalpation och enavlednings-EKG 
vid förmaksflimmerscreening och även om man hittar mer förmaksflimmer vid 
screening hos individer som har känt av hjärtklappning än de som inte har känt det.
I tredje delstudien analyserade vi sociodemografiska skillnader i deltagandet 
i STROKESTOP II studien samt jämförde resultaten mellan STROKESTOP I 
och STROKESTOP II studierna efter tillägg av två nya screening-mottagningar i 
STROKESTOP II.
I fjärde delstudien jämförde vi deltagare och icke-deltagare avseende socioekono-
misk status och hälsostatus och estimerade potentiell fångst av obehandlat förmaks-
flimmer inom icke-deltagargruppen.
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11.3 METODER
I delstudie I blev alla 75/76 åringar i Stockholm randomiserade 1:1 till interventions-
grupp eller kontrollgrupp. Individer i interventionsgruppen blev inbjudna att delta i 
förmaksflimmerscreening studien STROKESTOP II. Deltagare utan tidigare känt 
förmaksflimmer gjorde blodprov där man analyserade biomarkören NT-proBNP och 
delade deltagarna i en högriskgrupp eller en lågriskgrupp beroende på NT-proBNP 
nivå. De som hade NT-proBNP <125ng/L blev kategoriserade som lågriskgrupp och 
de med NT-proBNP≥125 ng/L blev kategoriserade till högriskgruppen. Alla gjorde 
enavlednings-EKG vid screeningbesöket medan högriskgruppen blev ombedda att 
göra förlängd screening och göra enavlednings-EKG mätningar fyra gånger dagligen 
under två veckors tid. Om förmaksflimmer diagnosticerades blev deltagarna remit-
terade till en kardiolog för bedömning och för att sätta in behandling om indikation 
fanns för blodförtunnande läkemedel.
I delstudie II blev alla deltagare i STROKESTOP II studien som inte hade sedan 
tidigare känt förmaksflimmer inkluderade. Sjuksköterskor och undersköterskor tog 
på screeningbesöket först radialis-pulsen hos deltagarna och registrerade om den var 
regelbunden eller oregelbunden. Därefter fick deltagarna göra ett enavlednings-EKG 
som registrerades som sinusrytm eller förmaksflimmer. Deltagarna svarade på frågan 
”har du känt av hjärtklappning” med ja eller nej.
I delstudie III blev alla som blev inbjudna att delta i STROKESTOP II inklud-
erade och samma datavariabler från STROKESTOP I deltagare var redan samlade. 
I STROKESTOP II studien infördes två ytterligare screening-mottagningar i de 
områden där man såg lägst deltagande i STROKESTOP I.  Hos deltagare tog man 
sjukdomsanamnes, tog blodprov och enavlednings-EKG vid screeningbesöket. Infor-
mation om de distrikt som alla inbjudna tillhörde användes för så kallad geo-mapping 
analys med hierarkisk Bayes metod för att studera skillnaderna i deltagande. Individ-
data på de socioekonomiska variablerna utbildningsnivå, inkomst, invandringsstatus 
samt civilstånd samlades anonymiserad för deltagare samt icke-deltagare från SCB. 
I delstudie IV använde vi registerdata från Patientregistret, läkemedelsregistret 
och Statistikmyndigheten för att jämföra deltagare och icke-deltagare avseende 
socioekonomiska och hälsodata. En random forest-modell tränades för att skatta 
sannolikheten för screeningdeltagande baserat på information om sociodemografi 
och sjukdoms- och läkemedelshistorik. De skattade sannolikheterna användes sedan 
för att skatta potentiellt screeningutbyte hos icke-deltagare.
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11.4 RESULTAT
I STROKESTOP II studien deltog 6868 individer och 6315 (91,9%) deltagare var 
utan tidigare känt förmaksflimmer. Av deltagarna utan känt förmaksflimmer hade 
3766/6315 (59,6%) NT-proBNP≥125 ng/L och gick vidare med två veckors inter-
mittenta enavlednings-EKG mätningar fyra gånger dagligen. Nytt förmaksflimmer 
hittades hos 4,4% (95% CI 3,7–5,1) av deltagarna som kategoriserades till högrisk-
gruppen. Hos alla deltagare utan tidigare känt förmaksflimmer hittades således nytt 
förmaksflimmer hos 2,6% (95% CI 2,2–3,0) genom screening. Förekomsten av känt 
förmaksflimmer ökade från 8,1% i deltagargruppen till 10,5% genom screening, en 
ökning på 30%. Hos de med nytt förmaksflimmer blev blodförtunnande behandling 
insatt hos 94,5% efter bedömning hos kardiolog och 96% av dessa hade kvar blod-
förtunnande behandlingen vid ettårsuppföljning.
I delstudie II blev 6159 deltagare inkluderade, varav 461 hade oregelbunden puls 
(7,5%). Av dessa hade 22 (4,8%) förmaksflimmer på enavlednings-EKG. Av de delt-
agare som bedömdes ha regelbunden puls hade 6 (0,1%) förmaksflimmer på enav-
lednings-EKG. Sensitiviteten av pulspalpation var 78,6% och positivt prediktivt 
värde 4,8%. Andelen deltagare med nytt förmaksflimmer var inte signifikant högre 
hos de som hade uppgivit att de känt av hjärtklappning. 
I delstudie III var deltagandet i STROKESTOP II högre hos de med hög utbild-
ning, hög inkomst, icke-invandrare samt gifta individer. Deltagandet jämfört mellan 
STROKESTOP I och STROKESTOP II ökade signifikant, inom alla socioekono-
miska variabler, kring de nya screening-mottagningarna. 
I delstudie IV var prevalensen av tidigare förmaksflimmer 17.9% hos icke-delt-
agare jämfört med 8.9% hos deltagare. De viktigaste faktorerna som förutspådde 
icke-deltagande var låg inkomst, sjukhusvistelse samt högre CHA2DS2-VASc poäng. 
Estimerat utbyte av obehandlat förmaksflimmer var högre bland icke-deltagare än 
deltagare.
11.5 SLUTSATSER
I en systematisk screening-studie för förmaksflimmer stratifierad för NT-proBNP, 
diagnosticerades 4,4% av deltagarna i högriskgruppen (NT-proBNP≥125 ng/L) med 
förmaksflimmer. Blodförtunnande behandling accepterades väl hos de med nytt 
förmaksflimmer. 
Puls palpation hade sämre diagnostiska prestanda jämfört med enavlednings-EKG 
för att diagnosticera förmaksflimmer och vi rekommenderar enavldenings-EKG 
framför pulspalpation för screening av förmaksflimmer. Hjärtklappning var inte 
associerad med nytillkommet förmaksflimmer.
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Decentralisering av screeningplatserna i STROKESTOP II hade en signifikant 
positiv verkan på deltagandet. Att öppna screeningplatser där man tidigare såg sämre 
deltagande hade en positiv inverkan på deltagandet genom alla delar av socioekon-
omiska nivå. 
Potentiellt utbyte av obehandlat förmaksflimmer var högre bland icke-deltagare än 
deltagare. Icke-deltagare hade högre CHA2DS2-VASc poäng som understryker att de 
har hög strokerisk och skulle kunna gynnas av förmaksflimmerscreening.
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12 ÍSLENSK SAMANTEKT
12.1 INNGANGUR
Hjarta og æðasjúkdómar eru algengasta dánarorsök hjá einstaklingum eldri en 15 
ára. Gáttatif sem algengasta klíníska hjartsláttaróreglan spilar þar stóran sess en það 
er áætlað að rúmlega 33 miljónir manns séu með gáttatif í heiminum. Gáttatif getur 
meðal annars aukið líkur á hjartabilun, heilaslagi og dauða. Það er vel þekkt að gát-
tatif auki hættuna á  heilaslagi, en þá áhættu er hægt að minnka um tvo þriðju með 
blóðþynnandi meðferð hjá þeim sem eru í áhættuhóp. Gáttatif getur verið nánast 
eða alveg einkennalaust, sérstaklega hjá eldri einstaklingum og er þar af leiðandi 
vangreint í þeim hópi. Gáttatif uppfyllir viðmið World Health Organization (WHO) 
um samfélagslega skimun þar sem það er algengur sjúkdómur, verður langvinnt van-
damál hjá flestum sjúklingum, það er til  meðferð, og spár segja til um að tíðnin muni 
aukast á næstu fimmtíu árum. Hvort að samfélagsleg skimun fyrir gáttatifi lækki 
tíðni heilaslaga og minnki þannig bæði þjáningar einstaklinga og borgi sig fyrir sam-
félagið í heild er spurning sem við vitum ekki ennþá svarið við en STROKESTOP I 
og STROKESTOP II rannsóknirnar leitast við að svara þeirri spurningu
12.2 MARKMIÐ
Í fyrstu rannsókn þessarar doktorsritgerðar var markmiðið að rannsaka hlutfall 
þátttakenda í STROKESTOP II sem hlutu greininguna gáttatif eftir að hafa verið 
flokkaðir í áhættuhóp eða ekki áhættuhóp samkvæmt niðurstöðu úr blóðprófi þar 
sem mælt var lífmerkið NT-proBNP. Við rannsökuðum einnig hversu stórt hlutfall 
þeirra sem greindust með gáttatif byrjuðu á blóðþynnandi meðferð og hversu stórt 
hlutfall var ennþá á blóðþynnandi meðferð að ári liðnu.
Í annarri rannsókn bárum við saman tvær skimunaraðferðir, annars vegar að þreifa 
púls á úlnlið til að greina óreglulegan hjartslátt og hins vegar einnar leiðslu hjar-
talínurit. Við skoðuðum einnig hvort að þeir sem höfðu fundið fyrir hjartsláttareink-
ennum voru líklegri til að greinast með gáttatif við skimun.
Í þriðju rannsókn bárum við saman félagsfræðilegan mun á þeim sem tóku þátt í 
STROKESTOP II og þeim sem ekki tóku þátt og bárum einnig saman STROKESTOP 
I rannsóknina og STROKESTOP II rannsóknina eftir að hafa bætt við tveim skimun-
arstöðvum í STROKESTOP II.
Í fjórðu rannsókn bárum við saman félagfræðilega og heilsufarslega þætti þátttak-
enda og þeirra sem ekki tóku þátt í STROKESTOP II. Við áætluðum einnig mögulegt 
hlutfall þeirra með meðhöndlanlegt gáttatif í þeim sem ekki tóku þátt í rannsókninni.
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12.3 AÐFERÐIR
Í fyrstu rannókninni voru allir íbúar í Stokkhólmi fæddir 1940 og 1941 slembi-
raðaðir 1:1 til að vera boðin þáttaka í STROKESTOP II eða vera viðmiðunarhópur. 
Hjá þeim sem tóku þátt í rannsókninni og ekki voru með þekkt gáttatif var tekið 
blóðpróf þar sem lífmerkið NT-proBNP var mælt. Svo var þeim skipt í tvo hópa, þar 
sem annar hópurinn var skilgreindur sem áhættuhópur ef NT-proBNP ≥125 ng/L. 
Allir þáttakendur sem ekki höfðu þekkt gáttatif fengu að taka einnar leiðslu hjar-
talínurit í skimunarheimsókninni. Þeir þátttakendur sem tilheyrðu áhættuhópnum 
tóku svo með sér einnar leiðslu hjartalínuritið heim og voru beiðnir að taka með 
því hjartalínurit fjórum sinnum á dag í þrjátíu sekúndur í senn næstu tvær vikurnar. 
Ef gáttatif greindist voru þátttakendurnir sendir til hjartalæknis til mats og sett inn 
blóðþynningarlyf ef ekki voru frábendingar fyrir því.
Í rannsókn tvö tóku þáttakendur í STROKESTOP II sem ekki höfðu þekkt gátta-
tif þátt. Hjúkrunarfræðingar og sjúkraliðar sem unnu við skimunina þreifuðu fyrst 
úlnliðspúlsinn á einstaklingunum í 30 sekúndur og skráðu hann sem reglulegan eða 
óreglulegan. Svo fengu þáttakendurnir að taka einnar leiðslu hjartalínurit og það 
var skráð sem sinus taktur eða gáttatif. Þáttakendurnir svöruðu einnig spurningunni 
„hefur þú fundið fyrir hjartsláttaróþægindum?“ með já eða nei.
Í þriðju rannsókninni skoðuðum við alla sem hafði verið boðið að taka þátt í 
STROKESTOP II með tilliti til félagsfræðilegu þáttanna: menntunarstig, tekna, inn-
flytjendastöðu og hjúskaparstöðu. Við höfðum þegar upplýsingar um um þessa þætti 
hjá þeim sem hafði verið boðið að taka þátt í STROKESTOP I. Í STROKESTOP 
II hafði tveim skimunarstöðvum verið bætt við frá því í STROKESTOP I, þar sem 
mælst hafði lægst þáttaka. Upplýsingar um sóknir allra sem var boðið voru notaðar 
til að búa til kort fyrir svokallaða „Geo-mapping“ greiningu samkvæmt stigveldi 
Bayes aðferð til að sýna muninn á þáttökunni.
Í fjórðu greininni bárum við saman félagsfræðilega þætti og heilsufarslega þætti 
hjá þátttakendum og þeim sem ekki tóku þátt en upplýsingar um það fengust hjá 
Sænskum skrám sem halda utan um þessar upplýsingar. Svokallað „random forest“ 
var þjálfað til að áætla stig fyrir tilhneigingu einstaklinga til að taka þátt. Þessi stig 
voru svo notuð til að áætla mögulegt hlutfall sjúkdóms hjá þeim sem ekki tóku þátt.
12.4 NIÐUSTÖÐUR
Alls svöruðu 6868 einstaklingar boðinu um að taka þátt í STROKESTOP II 
rannsókninni. 6315 (91,9%) af þeim reyndust ekki með þekkt gattatif. Hjá 3766 
(59,6%) einstaklingum mældist NT-proBNP gildi yfir 125ng/L og voru þeir eins-
taklingar skilgreindir sem áhættuhópur og beðnir um að taka einnar leiðslu hjar-
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talínurit fjórum sinnum á dag í tvær vikur. Í áhættuhópnum greindust 4,4% (95% 
CI 3,7–5,1) af einstaklingunum með nýtt gáttatif. Einn greindist með gáttatif við 
skimunarskoðunina í hópnum sem ekki var talinn áhættuhópur. Samanlagt greindust 
því 2,6% (95% CI 2,2–3,0) af öllum hópnum sem ekki hafði þekkt gáttatif með nýtt 
gáttatif við skimun. Algengi gáttatif jókst þar af leiðandi frá 8,1% í 10,5% hjá öllum 
þátttakendum sem er 30% aukning. NT-proBNP var sterkasti forspárþátturinn fyrir 
nýju gáttatifi í fjölbreytugreiningu hjá áhættuhópnum. Einstaklingar sem greindust 
með gáttatif hittu hjartalækni til mats og 94,5% fengu fyrirbyggjandi blóðþynnandi 
meðferð. Af þeim voru 96% ennþá á blóðþynnandi lyfjum að ári liðnu.
Í rannsókn tvö voru 6159 þáttakendur og þreifaðist óreglulegur púls hjá 461 
(7,5%). Af þeim greindust 22 (4,8%) með gáttatif á einnar leiðslu hjartalínuriti. Hjá 
þeim þáttakendum þar sem púlsinn var reglulegur greindust 6 (0,1%) manns með 
gáttatif. Næmni púlstökunnar var 78,6% og jákvætt forspárgildi var 4,8%. Hlutfall 
þátttakenda sem sögðust hafa fundið fyrir hjartsláttaróþægindum var ekki hærra 
meðal þeirra sem greindust með gáttatif.
Í þriðju rannsókninni sást betri þátttaka hjá einstaklingum sem voru með meiri 
menntun, hærri laun, hjá giftum einstaklingum og þeim sem ekki voru innfly-
tjendur. Þátttakan jókst, innan allra félagsfræðilegra breyta, í nánd við nýju 
skimunarstöðvarnar.
Í fjórðu rannsókninni voru 17.9% af þeim sem ekki mættu með áður þekkt gáttatif 
borið saman við 8.9% af þeim sem tóku þátt. Mikilvægustu þættirnir sem höfðu 
áhrif á þátttökuna voru lág laun, sjúkrahúsinnlagning og fleiri CHA2DS2-VASc stig. 
Áætlað ómeðhöndlað gáttatif var hærra (3,6%) meðal þeirra sem ekki tóku þátt en 
meðal þeirra sem tóku þátt (3,3%). 
12.5 ÁLYKTANIR
Í NT-proBNP lagskiptri skimun fyrir gáttatifi, greindust 4,4% af þáttakendunum í 
áhættuhópnum með nýtt gáttatif. Blóðþynnandi meðferð var sett inn hjá langflestum 
þeirra sem greindust með nýtt gáttatif og voru þeir ennþá á meðferð að ári liðnu.
Þreifing á púls er síðri leið til að greina gáttatif en einnar leiðslu hjartalínurit og við 
mælum með því að notast frekar við einnar leiðslu hjartalínurit við skimun fyrir gát-
tatifi. Hjartsláttaróþægindi hafa ekki forspárgildi fyrir greiningu gáttatifs við skimun.
Dreifing skimunarstaðanna hafði jákvæð áhrif á þáttöku og það að oppna skimun-
arstaði á svæðum þar sem áður var verri þátttaka hafði jákvæð áhrif á þátttöku meðal 
allra félagsfræðilegu breytna sem metnar voru.
Áætlað hlutfall ómeðhöndlaðs gáttatifs var hærra meðal þeirra sem ekki tóku þátt 
í STROKESTOP II en þeirra sem tóku þátt. Þeir sem ekki tóku þá voru með fleiri 
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CHA2DS2-VASc stig, sem bendir til þess að þeir séu með aukna áhættu á heilaslagi 
og myndu hagnast á að mæta í skimun. 
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